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A B S T R A C T
Background
Venous leg ulcers affect up to 1% of people at some time in their lives and are often painful. The main treatments are compression
bandages and dressings. Topical treatments to reduce pain during and between dressing changes are sometimes used.
Objectives
To determine the effects of topical agents or dressings for pain in venous leg ulcers.
Search methods
For this third update the following databases were searched: Cochrane Wounds Group Specialised Register (searched 9 May 2012);
The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 4); Ovid MEDLINE (2009 to
April Week 4 2012); Ovid MEDLINE (In-Process & Other Non-Indexed Citations May 08, 2012); Ovid EMBASE (2009 to 2012
Week 18); and EBSCO CINAHL (2009 to May 2 2012). No date or language restrictions were applied.
Selection criteria
Published or unpublished randomised controlled trials (RCTs) that evaluated the effects of topical agents or dressing for the treatment
of pain in venous ulcers were included.
Data collection and analysis
Two review authors independently performed trial selection, data extraction and risk of bias assessment.
Main results
Six trials (343 participants) evaluated EutecticMixture of Local Anaesthetics (EMLA): lidocaine-prilocaine cream for the pain associated
with ulcer debridement. The between-group difference in pain measured on a 100 mm scale was statistically significant in favour of
EMLA (MD -20.65, 95% CI -12.19 to -29.11). No significant between-group differences in burning or itching were observed.
Two trials (470 participants with venous leg ulcers) evaluated ibuprofen slow-release foam dressings for persistent venous leg ulcer pain.
Compared with local best practice, significantly more participants in the ibuprofen dressing group achieved the outcome of >50% of
the total maximum pain relief score between day 1 and day 5 than participants in the local best practice group (RR 1.63, 95% CI 1.24
to 2.15). The number needed to treat was 6 (95% CI 4 to 12). In the second trial, compared with an identical non-ibuprofen foam
dressing, there was no statistically significant difference in the proportion of participants experiencing slight to complete pain relief on
the first evening of treatment.Limited data were available to assess healing rates or adverse events.
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Authors’ conclusions
There is some evidence to suggest that ibuprofen dressings may offer pain relief to people with painful venous leg ulcers. EMLA (5%)
appears to provide effective pain relief during the debridement of venous leg ulcers. Further research should consider standardised pain
assessment methods and assess both the effect on ulcer healing and the impact of long term use of these treatments.
P L A I N L A N G U A G E S U M M A R Y
Topical agents or dressings for reducing pain in venous leg ulcers
Venous leg ulcers are often painful, both during and between dressing changes, and during surgical removal of dead tissue (debridement).
Dressings, topical creams and lotions have been promoted to reduce the pain of ulcers. Two trials tested a dressing containing ibuprofen,
however, the pain measures and time frames reported were different. One trial indicated that pain relief achieved over 5 days with
ibuprofen dressings could represent a clinically relevant reduction in pain. The other trial found no significant difference in the chance
of pain relief, measured on the first night of treatment, for ibuprofen dressings compared with foam dressings. This trial, however, was
small and participants were only followed for a few weeks, which may not be long enough to assess whether the dressing affects healing.
There was evidence from five trials that a local anaesthetic cream (EMLA 5%) reduces the post-procedural pain of debriding leg ulcers
but there was insufficient evidence regarding any side effects of this cream and its impact on healing.
B A C K G R O U N D
Description of the condition
Leg ulceration is estimated to have a point prevalence in Europe
and Australia of 0.1% to 0.2% of the adult population (Callam
1985; Graham 2003; O’Brien 2000). Prevalence increases with
age, and the condition is a chronic recurring problem with people
experiencing episodes of open leg ulceration lasting from a few
weeks to 50 years (Callam1987;Noonan 1998).Given this pattern
of ulceration, healing and recurrence, it has been estimated that up
to 1% of the population will be affected by leg ulceration at some
point. The majority of leg ulcers are caused by (are secondary to)
venous disease, other causes include arterial disease, vasculitis and
diabetes.
Pain is a frequently reported feature of venous leg ulceration
(Hamer 1994; Hofman 1997; Hyland 1994; Lindholm 1993;
Nelzen 1994; Noonan 1998; Phillips 1994). The precise preva-
lence of pain is difficult to determine due to methodological dif-
ferences between the trials and the use of predominantly hospital
populations. Reported figures for people experiencing severe or
continuous pain associated with a leg ulcer range from 17% to
65% (Franks 1994; Hofman 1997; Hyland 1994; Nelzen 1994;
Phillips 1994). It is accepted that when pain is a feature it has a
major impact on both sufferers’ and carers’ quality of life, with
sufferers stating that the worst aspect of having a leg ulcer is the
pain (Briggs 2007; Chase 1997; Douglas 2001; Ebbeskog 2001;
Hyde 1999; Lindholm 1993; Phillips 1994; Walshe 1995).
The cause of pain in people with venous leg ulcers is complex and
often poorly defined. The pathologies associated with leg ulcera-
tion (e.g. rheumatoid arthritis, vascular disease and diabetes) cause
pain with or without an ulcer present (Gibson 1998; Noonan
1998). The presence of an ulcer can cause additional pain through
two mechanisms. Firstly, pain is produced by the patient’s normal
response to wounding (i.e. through the inflammatory process as-
sociated with injury), and secondly, pain is produced by damaged
nerves. Leg ulceration may damage peripheral nerves by a variety
of processes, such ischaemia (lack of oxygen), infection and in-
flammation and this may cause a disruption in the way the nerves
respond to stimuli. This disruption can lead to a neuropathic com-
ponent to the pain, where sensitised nerves produce an exagger-
ated response to touch, i.e. a slightly painful stimulus may be felt
as extreme pain (Briggs 2007). Furthermore, pain is a symptom
of wound complications such as infection, skin maceration and
contact dermatitis, which may contribute to the overall leg ulcer
pain. In addition, leg ulcer treatments such as replacing dressings,
removing dead tissue (debridement) and firm bandages may cause
pain. In a recent international survey where practitioners from 11
European countries were questioned, leg ulceration was perceived
to be more painful than other chronic wounds. The practitioners
surveyed indicated that pain at dressing changes was common and
was caused by dressing adherence and wound cleansing (Moffatt
2002). It is clear from this that dressing choice and method of
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removal have an effect on venous leg ulcer pain, and there are a
number of trials where pain scores are reported as one of the char-
acteristics of dressing performance (Ohlsson 1994).
Another leg ulcer treatment is sharp debridement of slough and
necrotic tissue. This is advocated by some clinicians as the fastest
way of achieving a clean ulcer, which, in turn, is thought to im-
prove healing. It is thought that debridement reduces odour, low-
ers the risk of infection and improves the results of skin grafting
(Vanscheidt 2001). Debridement, however, is not without risks.
It is an extremely painful procedure (Hansson 1993), and people
with ulcers often ask clinicians to stop before the debridement is
complete because they are unable to tolerate the pain (Enander
Malmros 1990; Lok 1999). In addition, sharp debridement may
delay wound healing, as there is a risk of damaging healthy tissue
and underlying blood vessels (Vanscheidt 2001), and, as yet, there
is no direct evidence that debridement decreases the time taken
for a wound to heal Bradley 1999).
Non-systematic literature reviews and case trial reports have advo-
cated the use of occlusive dressings, such as semipermeable films
and hydrocolloids, as a method of pain relief (Hermans 1993;
Kannon 1995; Seeley 1994; Thomas 1989). There a number of
postulated theories that attempt to explain how an inert dress-
ing can provide pain relief. In a review of possible mechanisms,
Richardson 2010 suggests that there could be as many as 10 dis-
crete but interrelated mechanisms of action to explain pain reliev-
ing dressings. The authors suggest that it is possible that the pain
relief associated with the application of a new dressing to a chronic
wound could be due to both physiological and psychological fac-
tors, as opposed to the analgesic effect of the dressing alone.
Description of the intervention
Topical (external, surface) treatments such as the local anaesthetic
EMLA cream (Eutectic Mixture of Local Anaesthetics: lidocaine-
prilocaine cream) and analgesics have been applied directly into
ulcers in an attempt to relieve pain (e.g. Agrifoglio 2000). The
discovery of opiate receptors on peripheral nerve terminals has also
lead to the topical use of morphine in wounds (using hydrogel as a
carrier) (Stein 1995), and a number of trials have reported the anal-
gesic effect of morphine when applied topically to painful wounds
(Back 1995; Flock 2003;Twillman 1999;Zeppetella2004). This is
thought to work via local action on opioid receptors (Stein 1995).
This hypothesis was tested in the Ribeiro 2004 trial, which stud-
ied the bioavailability of topically-applied morphine to six partic-
ipants with cutaneous ulcers in a hospice setting. In five partici-
pants there was no evidence that the topical morphine had been
systemically absorbed (i.e. into the body), which supports the view
that the action is local. However, morphine metabolites were de-
tected in one participant who had a large pressure sore, suggesting
that morphine can be absorbed systemically via a wound with a
large surface area. This underlines the importance of research de-
signed to test the safety and efficacy of all topical agents in chronic
wounds.
Why it is important to do this review
This review aims to identify and summarise the evidence for the
effects of different dressings and topical treatments in the man-
agement of pain associated with venous leg ulcers.
O B J E C T I V E S
To conduct a systematic review of the effects of topical analgesics,
local anaesthetics and dressings used tomanage the pain associated
with venous leg ulceration (either persistent pain or treatment-
related pain, e.g. pain on leg ulcer debridement).
Specific questions addressed by the review are:
1. Are topical analgesics/anaesthetics effective in relieving
venous leg ulcer pain?
2. Which topical analgesics/anaesthetics are the most effective?
3. Are dressings effective in relieving the pain of venous leg
ulceration?
4. Which dressings are the most effective in relieving pain in
venous leg ulceration?
5. What is the relative effectiveness of topical analgesics or
anaesthetics compared to dressings in relieving pain in venous leg
ulceration?
6. What is the combined effect of dressings and topical
analgesics/anaesthetics in relieving pain in venous leg ulceration?
M E T H O D S
Criteria for considering studies for this review
Types of studies
Trials were eligible for inclusion if the following criteria applied:
• they were randomised controlled trials (RCTs) that
evaluated dressings and/or topical analgesics/anaesthetics used to
relieve the pain associated with venous leg ulceration. Either the
allocation of participants had to be described as randomised, or it
had to be evident that the intervention was assigned at random;
• cross-over trials were eligible, but only data from the first
period (if reported) were extracted in order to avoid carry-over
effects;
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• there was no restriction on the basis of language or
publication status.
Trials were excluded if the evaluation of pain was not the primary
aim, or if the pain was measured as a feature of the dressing (e.g.
pain on removal of the dressing).
Types of participants
We considered trials that recruited people of any age, in any care
setting who were described as having venous leg ulcers. As the di-
agnosis of venous leg ulceration varied between trials, a standard
definition of a venous leg ulcer was difficult to apply. Trials that in-
cluded people with leg ulcers, where the ulceration was reported to
be due to venous disease, were included irrespective of the method
of diagnosis used. People with arterial, diabetic, and neuropathic
ulcers were excluded, as it is unclear whether the nature of their
pain is similar to that of venous leg ulceration. People with ul-
cers reported to be due to sickle cell disease or rheumatoid arthri-
tis were also excluded, as the ulcer aetiology (cause) and systemic
disease processes involved in these conditions may mean that the
mechanisms and treatment of pain may differ from people with
pain from venous leg ulceration.
Trials that included a mixture of people with the following ulcer
aetiologies: arterial disease; mixed aetiology; neuropathic; and dia-
betes were included, if the outcomes for people with venous ulcers
were reported separately, or the original data were available.
Trials were excluded if the trial sample comprised people with
infected ulcers at baseline, as the nature of the pain associated with
infection may differ from the pain of leg ulceration.
Types of interventions
The primary intervention was the application of a topical anal-
gesic/anaesthetic or dressing with the aim of relieving the pain
associated with venous leg ulceration.
Topical analgesics/anaesthetics were defined as liquids, gels, pow-
ders, creams, foams or aerosols containing an analgesic or anaes-
thetic agent applied on or around the wound site. They can be
grouped into:
1. local anaesthetics;
2. non steroidal anti-inflammatory gels;
3. capsaicin;
4. opioids.
Dressings were defined as any dressing applied to the venous leg
ulcer with the intention of relieving pain. The groups of products
considered included:
1. film dressings;
2. hydrocolloids;
3. hydropolymer dressings;
4. foam dressings;
5. alginates;
6. gauze/gauze-type dressings;
7. hydrogels;
8. any other type of wound dressing.
Types of outcome measures
In order to be considered for inclusion a trial had to report at least
one of the primary outcomes (below).
Primary outcomes
1. Patient-reported pain scores using visual analogue scales
(VAS), verbal rating scales, numerical rating scales, pictorial
rating scales.
2. Pain scores from pain questionnaires such as the McGill
Pain Questionnaire, Brief Pain Inventory (Cleeland 1994).
3. Subjective global rating of pain relief (better/unchanged/
worse).
4. Summary measures such as SPID (Sum of Pain Intensity
Differences) and TOTPAR (Total pain relief achieved) (McQuay
1997).
Secondary outcomes
1. Ulcer healing rates (time from trial entry to complete ulcer
healing, proportion of ulcers completely healed in trial period or
changes in ulcer size).
2. Quality of life measures.
3. Adverse effects.
Trialswere excluded if surrogatemeasures of painwere used instead
of pain scores. These included analgesic consumption which may
not correlate with the amount of chronic pain experienced (Abbott
1992). Trials were excluded if they reported only data from quality
of life questionnaires that may highlight a broad category of bodily
pain, but are more likely to measure the impact of such pain rather
than the intensity of the experience.
Search methods for identification of studies
Electronic searches
For an outline of the search methods used in second update of this
review see Appendix 1.
For this third update we searched the following electronic
databases:
• Cochrane Wounds Group Specialised Register (searched 9
May 2012);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2012, Issue 4);
• Ovid MEDLINE (2009 to April Week 4 2012);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations May 08, 2012);
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• Ovid EMBASE (2009 to 2012 Week 18);
• EBSCO CINAHL (2009 to May 2 2012).
The following strategy was used to search The Cochrane Central
Register of Controlled Trials (CENTRAL):
#1 MeSH descriptor Analgesia explode all trees
#2 MeSH descriptor Analgesics explode all trees
#3 MeSH descriptor Capsaicin explode all trees
#4 capsaicin:ti,ab,kw
#5 MeSH descriptor Analgesics, Opioid explode all trees
#6 opioid:ti,ab,kw
#7 MeSH descriptor Anti-Inflammatory Agents, Non-Steroidal
explode all trees
#8 (non NEXT steroidal NEXT anti-inflammator* or NSAID*):
ti,ab,kw
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
#10 MeSH descriptor Administration, Topical explode all trees
#11 topical or local:ti,ab,kw
#12 (#10 OR #11)
#13 (#9 AND #12)
#14 MeSH descriptor Anesthetics, Local explode all trees
#15 ((topical or local) NEAR/3 (anaesthe* or anesthe*)):ti,ab,kw
#16 ((topical or local) NEAR/3 analgesi*):ti,ab,kw
#17 (#13 OR #14 OR #15 OR #16)
#18 MeSH descriptor Bandages explode all trees
#19 MeSH descriptor Hydrogels explode all trees
#20 MeSH descriptor Alginates explode all trees
#21 (dressing* or hydrocolloid* or alginate* or hydrogel* or “foam”
or “bead” or “film” or “films” or tulle or gauze or non-adherent or
“non adherent”):ti,ab,kw
#22 MeSH descriptor Ointments explode all trees
#23 (ointment* or “cream” or “creams” or “gel” or “gels”):ti,ab,kw
#24 (#18 OR #19 OR #20 OR #21 OR #22 OR #23)
#25 MeSH descriptor Pain explode all trees
#26 pain*:ti,ab,kw
#27 (#25 OR #26)
#28 (#24 AND #27)
#29 (#17 OR #28)
#30 MeSH descriptor Leg Ulcer explode all trees
#31 ((varicose NEXT ulcer*) or (venous NEXT ulcer*) or (leg
NEXT ulcer*) or (foot NEXT ulcer*) or (stasis NEXT ulcer*)):
ti,ab,kw
#32 (#30 OR #31)
#33 (#29 AND #32)
The search strategies for Ovid MEDLINE, Ovid EMBASE and
EBSCO CINAHL can be found in Appendix 2, Appendix 3 and
Appendix 4 respectively. The Ovid MEDLINE search was com-
bined with the Cochrane Highly Sensitive Search Strategy for
identifying randomised trials in MEDLINE: sensitivity- and pre-
cision-maximizing version (2008 revision); Ovid format (Lefebvre
2011). The EMBASE and CINAHL searches were combined with
the trial filters developed by the Scottish Intercollegiate Guidelines
Network (SIGN) (SIGN 2012).
Searching other resources
We searched the bibliographies of all relevant studies to identify
any further reports. The review authors also contacted other re-
searchers in the field.
Data collection and analysis
Selection of studies
All articles identified by the search strategy were coded as either
relevant, irrelevant, or uncertain by two review authors using the
inclusion and exclusion criteria as the decision framework. We
obtained copies of full papers for abstracts coded as relevant or
uncertain, and sought translations, if necessary. Eligibility for in-
clusion was confirmed by two review authors who independently
assessed the trials. Where uncertainty about inclusion remained,
where possible, additional information was sought from the orig-
inal authors and the review authors reached consensus through
discussion.
Data extraction and management
Details of trials eligible for inclusion were summarised using a data
extraction sheet. Research papers reporting the same trial were
identified and all relevant data from the papers were extracted. For
this third update, data extraction was completed by one review
author (MMSJ) and checked by a second (MB).
Assessment of risk of bias in included studies
For this third update, each included trial was appraised according
to the risk of bias assessment criteria described in the Cochrane
Handbook (Higgins 2011). Each validity item was assessed sep-
arately; ratings for each item were not combined into an overall
score. Each included trial was assessed by one author (MMSJ) and
checked by a second (MB). All disagreements were resolved by
discussion. The following criteria were applied:
1. Random sequence generation (selection bias)
Low risk of bias: adequate sequence generation was reported using
random number tables, computer random number generator, coin
tossing, or card/envelope shuffling.
High risk of bias: used a system involving dates, names, or ad-
mittance numbers for the allocation of participants. Such trials
were considered as quasi-randomised and were excluded from the
review.
Unclear risk of bias: did not describe one of the adequate methods,
but mentioned randomisation.
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2. Allocation concealment (selection bias)
Low risk of bias: a randomisationmethodwas described thatwould
not allow an investigator/participant to know or influence allo-
cation to an intervention group before an eligible participant en-
tered the trial, such as central randomisation or serially-numbered,
sealed envelopes.
High risk of bias: an inadequate method of allocation was used,
such as alternate medical record numbers or unsealed envelopes;
or there was information in the trial report indicating that inves-
tigators or participants could have influenced group allocation.
Unclear risk of bias: the trial report mentioned randomisation but
there was no information about the method used for allocation of
participants to treatment groups, or a method was reported that
was not clearly adequate.
3. Blinding of participants and personnel (performance bias)
This itemwas graded as ‘Low risk of bias’ for blinding participants,
‘Unclear risk of bias’ if the relevant information was not stated in
the trial report and ‘High risk of bias’ for unblinded participants.
4. Blinding of outcome assessment (detection bias)
This item was graded as ‘Low risk of bias’ for blinded outcome
assessment, ‘Unclear risk of bias’ if the relevant information was
not stated in the trial report and ‘High risk of bias’ for unblinded
outcome assessment.
5. Incomplete outcome data (attrition bias)
Low risk of bias: trial report included information on participant
withdrawals and indicates that all participants randomised were
included in the final analysis as either all participants completed
the trial, or participants that did not complete the trial were ac-
commodated in an intention-to-treat (ITT analysis).
High risk of bias: final analysiswas based on only those participants
who completed the trial, and did not included all participants
randomised.
Unclear risk of bias: unable to determine whether participants
included in final analysis were all participants initially randomised.
6. Selective reporting (reporting bias)
Low risk of bias: either the trial protocol was available and all of
the trial’s pre-specified outcomes were reported, or the trial report
described evaluation of expected outcomes and presented results.
High risk: the trial report did not include results for a key outcome
that would have been expected to be reported.
Unclear risk: insufficient information in the trial report to permit
judgement of low or high risk of bias.
7. Other sources of bias
Low risk of bias: the trial appeared to be free of other sources of
bias.
High risk of bias: there was a potential source of bias related to the
trial design (e.g., stopping early), or the trial has been claimed to
have been fraudulent, or had some other problem.
Unclear risk of bias: insufficient information to permit judgement
of low or high risk of bias.
Measures of treatment effect
We have grouped results according to the type of treatment for
pain relief (topical agents or dressings). We have undertaken sta-
tistical pooling of outcome data on groups of trials considered to
be sufficiently similar in terms of trial design and characteristics of
participants, interventions and outcomes. We have reported esti-
mates for dichotomous outcomes (e.g. between-group differences
in the proportions of participants experiencing pain relief ) as a risk
ratio (RR) with associated 95% confidence intervals (CI).We have
reported estimates for continuous data outcomes (e.g. between-
group differences in the change in pain score on a visual analogue
scale) as a mean difference (MD) with 95% CI.
Assessment of heterogeneity
The presence of clinical heterogeneity was assessed by comparing
the trials in terms of characteristics of co-interventions, setting and
population. We assessed the extent of statistical heterogeneity by
using the I-squared statistic (I²) (Higgins 2002; Higgins 2003).
This describes the percentage of the variability in effect estimates
that is due to heterogeneity rather than sampling error (chance).
We considered values greater than 50% as being indicative of sub-
stantial heterogeneity, in which case a random-effects model was
used to pool the results from different trials, otherwise a fixed-
effect model was used.
Data synthesis
We have presented a narrative overview of the included trials.
We analysed data using Cochrane RevMan software (version 5.1)
(RevMan 2011). If the event rates were less than 30%, dichoto-
mous outcomes for each trial were summarised as odds ratios with
95% confidence intervals (CI); if event rates exceeded 30% then
risk ratio (RR) was used (Deeks 1998). Where continuous out-
comes were measured in the same way across trials, we estimate
a mean difference (MD) with 95% CI. We planned to present
a standardised mean difference (SMD) where trials measured the
same outcome using different methods. Where trials reported ad-
verse events in sufficient detail (e.g. the number of participants
who experienced at least one adverse event) or proportions of ul-
cers healed following treatment, we analysed these data as dichoto-
mous. Results were pooled where a number of trials made the same
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comparisons and reported the same outcome in similar partici-
pants, otherwise, a narrative review was undertaken.
Sensitivity analysis
Where there was evidence of statistical heterogeneity (I² < 50%).
the included trials were explored to see what factors could have
contributed to the heterogeneity.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
One hundred eighty-five citations have been identified by the
searches toMay 2012. From this, the third update search (82 cita-
tions), one new trial was identified which met all of the inclusion
criteria and was included (Arapoglou 2011). Eight RCTs are now
included in this review (see Characteristics of excluded studies).
Two further trials were identified as relevant, but included people
with ulcers of mixed aetiology and did not present results sepa-
rately for participants with venous leg ulcers (Claeys 2011; Mosti
2010). We have contacted the trial authors for these data and the
trials are now awaiting assessment (see Characteristics of studies
awaiting classification). Forty-nine studies have been excluded to
date (see Characteristics of excluded studies).
Results will be presented first for the evidence for treatment-related
pain (section 1), and then for persistent pain (section 2).
Included studies
1. Interventions for treatment-related pain
1.1 EMLA compared with placebo or no anaesthesia (six
RCTs, 343 participants)
Six RCTs were included (Agrifoglio 2000; Hansson 1993; Holm
1990; Johnson 1992; Lok 1999; Rosenthal 2001). Five trials were
multi-centre RCTs undertaken in Canada (Rosenthal 2001), and
EU countries (Agrifoglio 2000; Hansson 1993; Johnson 1992;
Lok 1999). One was undertaken as a single-centre trial in Sweden
(Holm 1990). One trial was described as a two-part study, first an
open part and then a double-blind placebo controlled RCT part
(Holm1990).Data from the RCTphase only were included in this
review. Where reported, treatment settings included dermatology
clinics (Hansson 1993; Lok 1999; Rosenthal 2001) and outpa-
tient departments (Holm 1990). Three trials specified participants
with ulcers of venous aetiology (Agrifoglio 2000; Hansson 1993;
Lok 1999). Three included participants with venous leg ulcers,
arterial ulcers or ulcers of mixed aetiology (Holm 1990; Johnson
1992; Rosenthal 2001). Sample sizes ranged from 30 participants
(Holm 1990) to 110 participants (Agrifoglio 2000). Five trials re-
ported prescribing EMLA 5% cream (Hansson 1993;Holm1990;
Johnson 1992; Lok 1999; Rosenthal 2001). Agrifoglio 2000 did
not state the concentration of the EMLA preparation used. EMLA
was compared with a placebo cream in five trials (Agrifoglio 2000;
Holm 1990; Johnson 1992; Lok 1999; Rosenthal 2001). One
trial reported that EMLA was compared with no other anaes-
thetic or cream vehicle (Hansson 1993). Where reported, treat-
ment application time prior to debridement was either 30 minutes
(Holm 1990; Johnson 1992; Rosenthal 2001) or 30 to 45 min-
utes (Agrifoglio 2000; Lok 1999). Details of the sharp debride-
ment were reported by five of the trials (Agrifoglio 2000; Hansson
1993; Holm 1990; Johnson 1992; Lok 1999; Rosenthal 2001).
Pain after debridement was assessed by five trials using a visual
analogue scale (VAS) (Agrifoglio 2000; Hansson 1993; Johnson
1992; Lok 1999; Rosenthal 2001). Pain was assessed during the
procedure using a VAS and a 4-point verbal rating scale in one trial
(Holm 1990). Other outcomes included pain during re-dressing
of the ulcer and an overall procedure (cleansing and dressing) pain
score (Johnson 1992), the difficulty of performing the debride-
ment (Agrifoglio 2000), local reactions to the treatment (Holm
1990), local adverse events (Lok 1999), number of ulcers healed
(Hansson 1993), and participant-rated severity of local reactions
(Rosenthal 2001).
All six trials of EMLA were sponsored by Astra Zeneca AB.
2. Persistent venous leg ulcer pain
2.1 Topical ibuprofen (two RCTs, 810 participants)
Two RCTs that described the use of ibuprofen as a topical agent
in the form of a foam dressing that releases low-dose ibuprofen
(Biatain-Ibu (Coloplast A/S)) were included (Arapoglou 2011;
Gottrup 2008). Four reports previously classified as ’awaiting
assessment’ (Durante 2007; Domenech 2008; Jørgensen 2009;
Romanelli 2009b), one previously included report (Romanelli
2009a), and the report identified for inclusion in this update
(Arapoglou 2011), were judged to be reports from the samemulti-
centre trial. The previously included report by Romanelli 2009a
presented results for people with venous leg ulcers from the Italian
centre only. As the Arapoglou 2011 report presented results from
themulti-centre trial separately by wound aetiology (including ve-
nous leg ulcers), that were not available from the original report by
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Domenech 2008, Arapoglou 2011 was identified for this update
as the primary reference for this trial.
Arapoglou 2011 was a report of multicentre RCT across 12 EU
countries recruiting 853 inpatients and outpatients with painful
exuding wounds of various aetiologies. Results for 688 partici-
pants belonging to wound aetiology categories comprising more
than 25 patients (venous leg ulcers, arterial ulcers, mixed aeti-
ology, vasculitis and traumatic) were reported. Participants were
randomised to either ibuprofen foam dressing (Biatain Ibu) (n =
386, of whom 189 had venous ulcers) or local best practice (n =
302, of whom 159 had venous ulcers). Pain relief was evaluated
on a 5-point scale. Pain intensity was assessed using an 11-point
scale. The trial authors reported pain outcomes, categorised using
TOTPAR (total pain relief ) and SPID (summed pain intensity
difference).
Gottrup 2008was a multicentre RCT across EU countries that
randomised 122 people with leg ulcers to receive either a foam
dressing containing ibuprofen (Biatain-Ibu, Colopolast A/S,Den-
mark) (n = 62), or an identical foam dressing without ibuprofen
(Biatain Non-Adhesive, Coloplast A/S, Denmark) (n = 60). The
trialists assessed persistent pain relief on a 5-point scale and then
categorised these data as the number of participants experiencing
either pain relief or no pain relief.
The trials of ibuprofen foam were sponsored by Coloplast A/S
and all authors were members of the International Pain Advisory
Board for Coloplast A/S
2.2 Topical morphine (no trials)
OneRCTwas identified at the last review update which attempted
to address the question of efficacy of topical morphine on chronic
skin ulcers (Vernassiere 2005). The trial included people with leg
ulcers and pressure ulcers and the authors were contacted during
the last update to request data for only those people with leg ulcers
alone when the trial was awaiting assessment. We repeated this
request to the contact author for this update and did not receive a
reply so have excluded it from this update.
2.3 Lidocaine-containing dressing (no trials)
One citation was identified for this update that evaluated lidocaine
(Alvarez 2010). This was a conference abstract, and the trial au-
thors were contacted with a request for further information. The
trial author provided our group with the information required
(email communication) and we were able to conclude that pain
was a secondary outcome in this trial as the agent was not used
primarily to relieve pain. This trial was excluded then from this
review.
2.4 Hydrocolloid dressing (no trials)
Two trials, reported in abstract form only, that evaluated hydrocol-
loid dressings, were identified at the last update (Bruckner 2009;
Meaume 2008). Both trial authors were contacted during the last
update to request further information. For this update, we iden-
tified a full trial report (Bruckner 2010) for the Bruckner 2009
abstract and were able to conclude from the full report that the
dressing was not used primarily to relieve pain. A further request
for information regarding the other conference abstract (Meaume
2008) was made (email communication), but we were still unable
to confirm eligibility for inclusion in this review. Both trials were
therefore excluded at this update (Meaume 2008; Bruckner 2010).
Excluded studies
Forty-nine studies were excluded. Seven studies that were not
RCTs were excluded (Barghorn 1994; Freidman 1984; Lycka
1992;Mancini 2010;Ohlsen 1994; Peschen 1997;Wanger 1990).
One trial that was a cross-over design with no data reported by
group at cross-over was excluded (Jørgensen 2006).One case series
design study was also excluded (Flanagan 2006). Two trials were
excluded as pain outcome datawere not available (Larsson-Stymne
1990; Stacey 1999) and five trials were excluded as the primary
outcome was not pain (Alvarez 2010; Enander Malmros 1990;
Holst 1998; Nowak 1996; Romanelli 2008). Twenty-one tri-
als were excluded as the treatment evaluated was not a topical
analgesic/anaesthetic or dressing for relieving pain (Alvarez 2004;
Armstrong 1997; Arnold 1994; Brandrup 1990; Bruckner 2010;
Falabella 1998; Harcup 1986; Harvey 1985; Holloway 1989;
Klemp 1986; Larsen 1997; Laudanska 1988; Meaume 2008;
Mulligan 1986; Ohlsson 1994; Oluwatosin 2000; Poglinano
2010; Romanelli 2010; Sibbald 2011; Smith 1992; Woo 2009).
One trial was excluded as the sample were people with malignant
ulcers (MacGregor 1994). Two trials including people with dif-
ferent ulcer types where the data for only those with venous leg
ulcers was not available were excluded (Sibbald 2006; Vernassiere
2005). One trial that included participants with infected wounds
(Allen 1982) was excluded. Eight trials that did not include any
participants with venous leg ulcers (Carneiro 2003; Culyer 1983;
Foster 1994; Hughes 1989; Skog 1983; Twillman 1999; Shun
1983) were also excluded. One previously identified trial protocol
was excluded as the trial was never undertaken (Back 1995).
Risk of bias in included studies
We evaluated the risk of bias for each of the included trials and
the assessments are graphically represented in Figure 1 and Figure
2.
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Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included trials.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial.
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Allocation
Random sequence generation (selection bias)
For the trial reported by Arapoglou 2011 a computer-generated
list was described as the method of generating the randomisation
sequence and this trial was, therefore, classified as being at low risk
of bias for this domain. None of the other reports of included trials
described any details concerning the method for generation of the
randomisation sequence, and the trials were, therefore, classified
as being at an unclear risk of bias.
Allocation concealment (selection bias)
The Arapoglou 2011, Gottrup 2008 and Hansson 1993 reports
each described the use of sealed envelopes to conceal group al-
location. The envelopes, however, were not described as opaque
or sequentially numbered. These trials were classified as being at
unclear risk of bias. No details regarding allocation concealment
were reported by any of the other included trials. These were also
classified as presenting an unclear risk of bias.
Blinding
Blinding of participants and personnel (performance bias)
Arapoglou 2011 and Hansson 1993 both reported results from
open-label trials, and were, therefore, classified as being at high
risk of bias for this domain. All of the other reports for included
trials described them as being double-blind and were classified as
being at low risk of bias.
Blinding of outcome assessment (detection bias)
Arapoglou 2011 and Hansson 1993 both reported results from
open-label trials and were therefore classified as being at high risk
of bias for this domain. All of the other reports for included trials
described double-blind designs and were classified as being at low
risk.
Incomplete outcome data
None of the included trial reports were considered at high risk
of bias for this domain. One report contained insufficient detail
regarding the presence, or absence, of withdrawals and was classi-
fied as being at unclear risk of bias (Lok 1999). All other included
reports were classified as being at low risk of bias for this domain.
Selective reporting
A complete clinical report was available for one of the included
trials that indicated there was no selective reporting bias evident (
Johnson 1992). For the remaining seven included trials (Agrifoglio
2000; Arapoglou 2011; Gottrup 2008; Hansson 1993; Holm
1990; Lok 1999; Rosenthal 2001), the peer-reviewed report did
not indicate that any selective reporting may have been evident,
and these were also classified as being at low risk of bias.
Other potential sources of bias
In the Holm 1990 trial, the trial authors reported that the ran-
domisation process did not take into account people with diabetes,
and that, as such, there was an imbalance of people with diabetes
across the treatment groups. This trial was considered to be at high
risk of other bias. No other sources of bias were detected in any of
the other included trial reports.
Effects of interventions
The results of the review are presentedwith reference to the original
questions posed.
1. Are topical analgesics/anaesthetics effective in
relieving venous leg ulcer pain?
EMLA for debridement pain
Six trials involving 343 participants with venous leg ulcers com-
pared EMLA cream with placebo cream or no anaesthetic for the
treatment of pain caused by leg ulcer debridement (Agrifoglio
2000; Hansson 1993; Holm 1990; Johnson 1992; Lok 1999;
Rosenthal 2001). Five of the trials reported a statistically signifi-
cant reduction in the pain outcome measured when EMLA (5%)
was applied topically for 30 to 45minutes under occlusion prior to
debridement (Agrifoglio 2000; Hansson 1993; Holm 1990; Lok
1999; Rosenthal 2001). Johnson 1992 reported no statistically
significant between-group difference.
The characteristics of the trials are summarised inTable 1.Method-
ologically the trials were considered similar. All six trials measured
pain as the primary outcome using a 100 mm VAS. All the trials
recruited people with venous leg ulcers of less than 50 cm² area
from dermatology and vascular centres.
Outcome 1: pain score at debridement
The six trials were considered sufficiently similar to pool. The ob-
served I² was 53%. Meta-analysis (random-effects) demonstrated
that there was a statistically significant reduction in pain scores
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measured on a VAS 0-100 mm at debridement associated with
EMLA cream (MD -20.65, 95% CI -29.11 to -12.19; P value
< 0.00001) (Analysis 1.1). This represents a clinically significant
reduction in pain associated with EMLA.
The trials were explored to see what factors could have contributed
to the statistical heterogeneity. Three trials included people with
diabetes (Hansson 1993; Holm 1990; Lok 1999), whilst three ex-
cluded people with diabetes on the basis that diabetic neuropa-
thy (which is frequently associated with reduced sensory percep-
tion) might confound the result (Agrifoglio 2000; Johnson 1992;
Rosenthal 2001). Two trials restricted their sample to people who
had previously experienced pain at debridement (Johnson 1992;
Rosenthal 2001), whereas the other trials included all people with
venous leg ulcers.
One trial administered theVAS during the debridement procedure
(Holm 1990), whilst in the remainder the VAS was administered
after the procedure. Excluding this trial from the analysis reduced
both the observed between-trial heterogeneity (I² = 29%) and the
overall effect estimate (MD (fixed-effect) -18.72, 95% CI -24.41
to -13.02; P value < 0.00001).
One trial reported that participants were given oral analgesia in
addition to the EMLA cream (Lok 1999). Excluding this trial
from the analysis did not reduce the observed heterogeneity (I² =
63%; MD -21.87 (random-effects), 95% CI -32.01 to -11.73; P
value < 0.0001). None of the other trials recorded oral analgesic
intake and therefore the impact of this is uncertain.
The Johnson 1992 trial may also account for some of the het-
erogeneity, because the cleansing did not only include sharp de-
bridement, which is very painful, but also included rubbing the
wound with gauze and irrigating the wound which are likely to
be less painful procedures. Excluding this trial from the analysis
reduced the observed heterogeneity (I² = 18%) and increased the
overall effect estimate (MD (fixed-effect) -23.38, 95% CI -29.43
to -17.14; P value < 0.00001).
The meta-analysis of the six trials suggests improved pain relief
whenEMLA is used, but the results should be viewedwith caution,
given the observed heterogeneity.
Outcome 2: ulcer healing
Only one trial reported healing outcomes. This trial favoured
placebo in terms of the number of ulcers healed at the end of
the trial; 1/22 healed in the EMLA group compared with 5/21
in the control group, although this is not a statistically significant
difference (OR for healing with control 6.56, 95% CI 0.70 to
61.85) (Hansson 1993) (Analysis 1.2). The interpretation of this
finding is not straightforward, however, since the groups were not
matched for baseline ulcer duration (EMLA: median 9.5 months
(range, 1-168); Control: 5 months (range, 1-504)). Findings from
prognostic trials have suggested that the two most important pre-
dictors of delayed healing in participants with venous leg ulcer-
ation are baseline ulcer duration and wound surface area; people
with larger and more chronic wounds are more likely to experi-
ence longer times to healing (Margolis 2000;Margolis 2004). The
period between individual debridement sessions ranged from two
to nine days and the follow-up time varied considerably for each
participant (one participant visited the clinic once a month with
a follow-up time of 140 days. The range for the EMLA group
was 38 to 40 days). Since the follow-up time varied considerably
for each participant, the comparison of the healing outcomes may
not be valid. The trial was also potentially underpowered to detect
healing since only six events occurred.
No other included trial examined healing as an outcome and,
therefore, the impact of the local anaesthetic on healing cannot be
judged.
Outcome 3: adverse effects
Three trials reported the incidence of burning and itching in 233
participants (Agrifoglio 2000; Johnson 1992; Lok 1999). There
was no statistically significant difference between rates of adverse
events for EMLAandplacebo creams (OR for burningwithEMLA
1.72, 95% CI 0.74 to 4.01, Analysis 1.3; OR for itching with
EMLA 1.68 95%CI 0.64 to 4.38, Analysis 1.4).
2. Which topical analgesics/anaesthetics are the most
effective?
No trials were identified that could answer this question.
3. Are dressings effective in relieving the pain of
venous leg ulceration?
Low-dose topical ibuprofen-containing dressings (Biatain-
Ibu) for persistent pain
Outcome 1: pain relief/pain scores
We consulted members of the Cochrane Pain, Palliative & Sup-
portive Care Review Group with a view to pooling the data from
two trials evaluating ibuprofen-containing dressings (Arapoglou
2011; Gottrup 2008), however, it was agreed that the pain mea-
sures and time frames reported were too heterogeneous for the
data to be pooled. Therefore, where the between-group difference
was statistically significant, we have estimated a NNT (number
needed to treat) with 95% CI. The NNT estimates the number
of people who would need to use the topical ibuprofen dressing
for one person to achieve significant pain relief.
Gottrup 2008 observed that on the first evening of treatment,
46 participants out of 62 (74%) achieved some pain relief with
the ibuprofen-containing foam compared with 35/60 (58%) with
the plain foam. The between-group difference was not statistically
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significant although the comparison is underpowered (RR 1.27,
95% CI 0.98 to 1.65; p=0.07) (Analysis 2.1).
In the Gottrup 2008 trial, the average pain scores reported indi-
cated a reduction of 2.7 in the ibuprofen foam group (from 6.8 to
4.1) compared with 2.0 in the foam dressing group (6.6 to 4.6)
(no variance data reported). This represents an overall percentage
pain reduction of 40% and 30%, respectively, from baseline pain
scores (i.e. a difference of 10% between the groups). A mean be-
tween-group difference with 95% CI could not be estimated for
this review.
Arapoglou 2011
The proportion of patients with a summed pain relief score of
more than 50% of the total maximum pain relief score from day
1 to day 5 was reported (TOTPARD5>50%). The authors reported
that 49% of participants achieved more than 50% pain relief in
the ibuprofen-containing dressing group compared to 30% in the
comparator foam dressing group. The between-group difference
was statistically significant in favour of the ibuprofen-containing
dressing (RR 1.63, 95% CI 1.24 to 2.15; p=0.0006) (Analysis
3.1).
We estimated a NNT of 6 (95% CI 4 to 12). This can be inter-
preted as 19% more participants experienced greater than 50%
pain relief in the ibuprofen-containing dressing group compared
to the placebo group. This could represent a clinically relevant
reduction in pain, especially if combined with other methods of
pain relief (Dworkin 2008).
Outcome 2: ulcer healing
Gottrup reported similar rates of complete ulcer healing in the
two groups after six weeks: 16% (10/62) with ibuprofen foam and
15% (9/60) with standard foam (Gottrup 2008). The between-
group difference was not statistically significant (OR 0.85, 95%
CI 0.32 to 2.26) (Analysis 2.2). Arapoglou 2011 did not report
ulcer healing.
Outcome 3: adverse effects
Gottrup reported that 12 participants experienced 21 adverse
events in the ibuprofen foam group while in the comparator group
there were 10 adverse events in seven participants (Gottrup 2008).
There were no serious dressing-related events in the trial. The be-
tween-group difference in the proportion of participants experi-
encing adverse events was not statistically significant (OR 1.46,
95% CI 0.52 to 4.11) (Analysis 2.3). In the ibuprofen group there
was local infection in three participants, eczema in two partici-
pants, blisters in two participants, urticaria in one patient, pain in
one ulcer and 12 other participants had 13 incidences said to be
unrelated to the dressing. In the standard foam group there were
local wound infections in two participants, bullae in one patient,
eczema in two participants, blisters in one patient, and another
four participants had six events reported to be unrelated to the
dressing. Arapoglou 2011 did not report adverse events.
4. Which dressings are the most effective in relieving
pain in venous leg ulceration?
No trials were identified that could answer this question. In section
3 above, the two trials evaluating dressings are summarised.
5. What is the relative effectiveness of topical
analgesics or anaesthetics compared to dressings in
relieving pain in venous leg ulceration?
No trials were identified that could answer this question.
6. What is the combined effect of dressings and
topical analgesics/anaesthetics in relieving pain in
venous leg ulceration?
No trials were identified that could answer this question.
D I S C U S S I O N
Persistent pain
Two trials that evaluated low-dose ibuprofen releasing foam dress-
ings reported this outcome. Both trials reported that the between-
group difference in pain relief assessment scores was statistically
significant.However, variance data for the differenceswere not pre-
sented. ’Pain relief achieved’ was assessed in different ways across
these trials; as pain scores on a visual analogue scale (11 points: 0
to 10), and as total pain relief achieved (TOTPARD5<50%). These
differences in the way pain relief was assessed, coupled with the
unavailability of variance data, limited any assessment of between-
group differences in persistent pain across these trials for this re-
view.
One trial indicated that there is a statistically significant between-
group difference in favour of ibuprofen-containing dressings for
TOTPARD5<50% (Arapoglou 2011). However, this trial was con-
sidered to be at a high risk of performance and detection bias as
it was described as an open study design. As the primary outcome
for this review, pain, whichever way it is measured, may be subject
to observer or measurement bias, this should be taken into con-
sideration when considering the pain outcomes reported by this
trial. Both trials that evaluated low-dose ibuprofen releasing foam
dressings were considered at unclear risk of bias for allocation con-
cealment, as the method of treatment group allocation was not
reported.
Both trials were of relatively short duration (only a few weeks
long), and undertaken in people with chronic wounds where the
dressing application was for the treatment of pain. One of the tri-
als excluded participants who “had painful ulcers that had been
resistant to analgesic treatment over the last six months” (Gottrup
2008). For this trial we were able to estimate the between-group
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difference in the proportion of participants who achieved some
pain relieve on the first evening of treatment, which was not sta-
tistically significant. This trial also reported the proportion of ul-
cers healed at follow-up. The between-group difference was not
statistically significant.
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID).
Systemic NSAIDs are associated with a number of important ad-
verse effects including: effects on the kidneys, exacerbation of
asthma in susceptible people, and problems in the gastrointesti-
nal tract including ulceration (Bandolier Extra 2005). Topical
NSAIDs can be given in lower doses, and their adverse event pro-
file is better (Bandolier Extra 2005). This observation, however,
is based on studies amongst people predominantly with arthritic
pain, where topical NSAIDs are massaged into intact skin. Only
one of the include trials in the present review that evaluated a top-
ical NSAID reported on adverse events (Gottrup 2008), conclud-
ing that because there were few dressing-related events reported
during the trial, that this indicated good dressing safety.
The variability in the pain assessment method and the reporting
of pain outcomes across trials, coupled with the potential bias as-
sociated with un-blinded outcome assessment, makes interpreta-
tion of the current evidence-base for topical NSAIDs in the man-
agement of chronically painful leg ulcers difficult. We would rec-
ommend that future trials of topical NSAIDs for this condition
need to consider a standardised pain assessment method to facil-
itate interpretation of results across trials, be of longer duration
and be better reported, in order to assess both the efficacy for pain
management and the safety and tolerability along with their effect
on ulcer healing.
Treatment-related pain
Six trials focused on the relief of one aspect of pain, namely pain
associated with leg ulcer debridement. These trials all evaluated
EMLA cream versus placebo for the sharp debridement of venous
leg ulcers. The rationale for the proliferation of research effort in
this area appears to be based on two factors. Firstly, that debride-
ment is a painful procedure (Hansson 1993), with participants
often asking clinicians to stop before it is complete as they are
unable to tolerate the pain (Lok 1999), and, secondly, the belief
that the removal of necrotic and devitalised tissue improves the
healing potential of a leg ulcer (Hansson 1993; Holm 1990; Lok
1999).
The pooled effect across the six trials for the mean between-group
difference in the VAS score at debridement was statistically sig-
nificant in favour of EMLA. The largest between-group effect es-
timate in favour of EMLA that was observed was for one trial
that assessed pain during the ulcer debridement procedure (Holm
1990). This may in part be due to the specific effect of EMLA on
the procedural pain associated with debridement, as opposed to
the chronic, background pain that is associated with venous leg ul-
cers. The remaining five trials all assessed pain after debridement.
The between-trial heterogeneity that was observed for this com-
parison was reduced in the sensitivity analyses excluding the trial
where pain was assessed during debridement (Holm 1990), and
excluding one trial where the cleansing procedure included rub-
bing the wound (Johnson 1992). The effect estimates remained
statistically significant.
Sharp debridement is an aggressive treatment involving scalpel,
scissors, a sharp curette and forceps. The removal of necrotic and
sloughy material from a wound bed is proposed to reduce the risk
of infection, reduce odour and promote granulation tissue, and
is an accepted therapeutic activity in wound healing (Lok 1999).
It has been suggested that sharp debridement is the quickest way
to achieve a clean ulcer and that it improves the result of skin
grafting and the healing potential of the ulcer (Vanscheidt 2001).
Steed 1996 reported the effect of extensive debridement on the
healing of diabetic foot ulcers by pooling data from 10 treatment
centres, reporting that those centres that performedmore frequent
debridement had better healing rates. The trial by Lok 1999 in-
cluded in this review reported that themean ulcer size at follow-up
was inversely proportional to the number of debridements under-
taken during the trial. However, the between-group difference in
the proportion of ulcers healed at the end of treatment reported by
another included trial (Hansson 1993) was not statistically signif-
icant. Improved healing may be attributable to aspects of wound
care other than debridement.
The pooled effect estimate from five trials included in this review
indicates that people with venous leg ulcers could expect their
post-debridement pain to be reduced by 19 mm on a 100 mm
VAS if given EMLA. Evidence from one trial indicates that the
procedural pain associated with ulcer debridement is also signif-
icantly reduced with EMLA. However, none of the included tri-
als provided adequate detail in the trial report regarding the ran-
domisation sequence generation or any concealment of allocation
procedure and are therefore considered to be at an unclear risk of
selection bias. The results should therefore be interpreted with
caution, given that theremay be systematic differences in the char-
acteristics of the participants receiving EMLA and those receiving
placebo in these trials. One of the trials (Hansson 1993) was also
considered to be at a high risk of performance and detection bias
as it was described as an open trial.
The impact of local anaesthetics on ulcer healing was not suffi-
ciently evaluated by the included trials in this review. A review of
in vitro studies has suggested that local anaesthetics reduce gran-
ulocyte activity, inhibit fibroblast growth and collagen synthesis
(Dahl 1994). A reduction in leukocyte activity in surgical wounds
has also been reported (Eriksson 1992). Conversely, no significant
differences between EMLA and placebo on the healing of exper-
imentally-generated burns at two weeks were evident from one
within-subject study (Pedersen 1996).The clinical implication of
these experimental studies for the effects of EMLA on the healing
of chronic wounds has yet to be determined through adequately
designed randomised controlled trials.
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There is still a paucity of evidence for the effects of topical agents
or dressings for pain in venous leg ulcers from robust, adequately
reported RCTs to inform this area of wound care practice. A pos-
sible reason could be that people with venous leg ulcers are not
considered a sufficiently large, discrete group who have pain war-
ranting study, unlike, for example, those with osteoarthritis, low
back pain or postoperative pain. If a separate reviewwas conducted
exploring systemic analgesia or neuromodulation (e.g. Transcu-
taneous Electrical Nerve Stimulation (TENS)) the evidence base
might be different. Pain specialists might not be aware of the need
for robustly designed and clearly reported RCTs to evaluate the
effects of topical agents and dressings for pain management and
healing in people with venous leg ulcers. Similarly, wound care
specialists may be aware of the need for well designed RCTs, but
lack the specialist knowledge of pain management to develop and
manage trials that evaluate analgesic interventions.
Limitations
There are limitations to the findings from this review. In addition
to the electronic searches of bibliographic databases, the search
for evidence for this review included handsearching and contact
with trialists. Although this search strategy was comprehensive,
the presence of a publication bias may still be evident. All of the
published trials in this review reported statistically significant dif-
ferences. The unpublished trial found during searching reported
no difference (Johnson 1992). There may be other unpublished
trials with similar results that we have been unable to identify.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
On the basis of two trials, there is some evidence that foam dress-
ings containing ibuprofen provide pain relief for some people with
painful venous leg ulcers. The release of ibuprofen into the wound
bed is dependent on the presence of wound exudate. This treat-
ment would, therefore, not be an option for pain management for
people with wounds that have low levels of, or no, exudate. Evi-
dence from six trials indicates that EMLA (5%) significantly re-
duces pain during the debridement of venous leg ulcers compared
with placebo or no anaesthetic. Existing trials examining EMLA
versus placebo are designed to assess pain, but do not address the
related question of whether debridement is necessary.
The decision to debride a venous leg ulcer needs to be made with
knowledge of the evidence-base, clinical need and the risks associ-
ated. Severe pain is a clearly documented risk associated with de-
bridement and EMLA 5% cream is the only topical anaesthetic for
which this review has found evidence of analgesic efficacy. EMLA
applied for 30 to 45 minutes in a dose of 1 g to 2 g/ 10 cm² sig-
nificantly reduces the pain from sharp debridement and decreases
the incidence of post-debridement pain. However, most trials to
date have excluded people with ulcers greater than 50 cm². The
analgesic efficacy of EMLA in people with larger ulcers is currently
not known.
It should be noted that in certain countries, specifically the UK,
EMLA is not licensed to be applied directly to wounds. It is be-
lieved that EMLA is currently approved as a topical anaesthetic
for the debridement of leg ulcers in Belgium, Denmark, Finland,
France, Germany, Netherlands, Norway, Portugal, Spain, Sweden
and Switzerland (Blanke 2003).
Implications for research
This review highlights the need for further randomised controlled
trials to examine the effectiveness of local interventions to relieve
the underlying pain of venous leg ulceration in long-term follow-
up studies. Further research is required todeterminewhether dress-
ings that incorporate ibuprofen reduce pain significantly. Further
trials are also warranted to assess methods of pain relief during the
actual debridement procedure and that evaluate EMLA in people
with venous leg ulcers greater than 50 cm2. Participants should be
followed-up for sufficient time to assess healing and to measure
the incidence of adverse effects. Further research is also required to
determine whether debridement of venous leg ulcers aids healing.
The methodologies developed to assess interventions in the man-
agement of other chronic pain syndromes could be adapted to
address questions related to leg ulcers (McQuay 1997). Specific
outcome measures need to be developed for this group of people.
In the absence of such measures, trials should follow the guidance
outlined in the IMMPACT (Initiative on methods, measurement
and pain assessment in clinical trials) recommendations. IMM-
PACT recommends four core chronic pain outcomes of which at
least two should be measured in a trial (Dworkin 2008). These
are:
1. Intensity of pain over time, assessed by a numerical rating
scale.
2. Impact of physical functioning assessed by the multi-
dimensional pain inventory, or the brief pain inventory.
3. Peoples’ overall assessment of improvement assessed by the
Patient Global Impression of Change scale.
4. Emotional functioning assessed by the Beck depression
inventory and the profile of mood states.
In addition from a wound management perspective:
1. Time to complete healing.
2. Adverse effects.
Baseline comparability using the following criteria would also be
desirable:
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1. Baseline pain scores.
2. Psychological measures (anxiety, mood, depression).
3. Analgesic consumption.
Further trials should adopt a best practice methodology, use con-
sistent outcomes and be better reported in line with the CON-
SORT (Consolidated Standards of Reporting Trials) guidelines for
the reporting of RCTs (Schulz 2010).
A C K N OW L E D G E M E N T S
Thanks go to Professor FREllis, Professor of Anaesthesia, and Pro-
fessor SJ Closs, both University of Leeds, for support and advice
throughout the project. Thanks are also due to Stefan Lillieborg,
Astra Pain Control AB, Sweden for help with trial identification
and retrieval of unpublished data. Thanks to Sheena Derry and
Phil Wiffen, Pain Research Oxford for advice on data analysis.
Finally, we would like to extend our thanks to the following who
refereed the review formethodological rigour, readability and clin-
ical relevance: Wendy Greenshields, Matthew Bradley, Deborah
Hofman, Kate Seers, Peter Johnston and Christine Palmer and
Cochrane Wounds Group Editors (Nicky Cullum and Andrew
Jull), and editorial staff (Sally Bell-Syer, Sally Stapley and Ruth
Foxlee) for their comments to improve the review. Thanks also to
copy editor Elizabeth Royle.
R E F E R E N C E S
References to studies included in this review
Agrifoglio 2000 {published and unpublished data}
∗ Agrifoglio G, Domanin M, Baggio E, Cao, P, Alberti
AN, Borin AR, et al.EMLA anaesthetic cream for sharp
debridement of venous leg ulcers: a double masked placebo
controlled study. Phlebology 2000;15(2):81–3.
Domanin M. A multi-centre, double-blind, placebo-
controlled study of a lidocaine/prilocaine cream (EMLA
5%) used as a topical anaesthetic for sharp debridement of
venous leg ulcers. 9th European Conference on Advances
in Wound Management; 1999, 9-11 November Harrogate
UK. 1999.
Arapoglou 2011 {published data only}
∗ Arapoglou V, Katsenis D, Syrigos KN, Dimakakos EP,
Zakopoulou N, Gjødsbøl K, et al.Analgesic efficacy of an
ibuprofen-releasing foam dressing compared with local best
practice for painful exuding wounds. Journal of Wound Care
2011;20(7):319–25.
Dimikakos EP, Arapoglou V, Katsenis K, Glynn C,
Schäfer E, Andersen MB, et al.An ibuprofen-releasing
foam dressing provided clinically relevant pain relief for
exuding, painful, chronic and traumatic wounds of different
aetiologies. EWMA Journal. 2011; Vol. 11:2 Suppl.
Doménech RP, Romanelli M, Johannesen N, Ram A,
Schäfer E. Effects of an ibuprofen releasing foam on wound
pain: results from an international, comparative real life
study on painful, exuding wounds. EWMA Journal 2008;8
(2):179, Abstract 151.
Doménech RP, Romanelli M, Tsiftsis DD, Slonková V,
Jortikka A. Effect of an ibuprofen-releasing foam dressing
on wound pain: a real-life RCT. Journal of Wound Care
2008;17(8):342–8.
Durante C, Scalise A,Maggio G. Reducing wound pain with
an ibuprofen dressing in real life settings. 17th Conference
of the European Wound Management Association; 2007, 2-
4 May; Glasgow, Scotland. 2007:172.
Jørgensen B, Polignano R, Mantovani M, Orsted H. Effects
of a foam dressing with ibuprofen on wound pain from
arterial leg ulcers and vasculitic ulcers. EWMA Journal
2009;9(2):193, Abstract P194.
Maggio G, Scalise A, Durante C. Improved health related
activities of daily living for patients with wound pain treated
with ibuprofen foam dressing. 17th Conference of the
European Wound Management Association; 2007, 2-4
May; Glasgow, Scotland. 2007:Poster no 163.
Romanelli M, Dini V, Polignano R, Bonadeo P, Maggio
G. Ibuprofen slow release foam dressing reduces wound
pain in painful exuding wounds preliminary findings from
an international real life study. Journal of Dermatological
Treatment 2009;20(1):19–26.
Romanelli M, Fogh C, Kusch I. Effects of a foam dressing
with ibuprofen on wound pain from venous leg ulcers and
mixed venous arterial leg ulcers. EWMA Journal 2009;9(2):
194, Abstract P195.
Gottrup 2008 {published and unpublished data}
Gottrup F, Jørgensen B, Karlsmark T, Sibbald RG,
Rimdeika R, Harding K, et al.Less pain with Biatain Ibu:
initial findings from a randomised, controlled, double-
blind clinical investigation on painful venous leg ulcers.
International Wound Journal 2007;4(Suppl 1):24–34.
Gottrupp F, Jørgensen B, Karlsmark T, Sibbald G, Rimdeika
R, Harding K, et al.Reducing persistent wound pain with an
ibuprofen-foam: A randomised, controlled, double-blind
clinical investigation on the treatment of painful venous leg
ulcers [Poster no: 154]. 17th Conference of the European
Wound Management Association; 2007, 2-4 May; Glasgow,
Scotland. 2007.
∗ Gottrupp F, Jørgensen B, Karlsmark T, Sibbald G,
Rimdeika R, Harding K, et al.Reducing wound pain in
venous leg ulcers with Biatian Ibu: A randomised controlled
double blind clinical investigation on performance and
safety. Wound Repair and Regeneration 2008;16:615–25.
Hansson 1993 {published and unpublished data}
Hansson C, Holm J, Stefan L, Syren A. Repeated treatment
16Topical agents or dressings for pain in venous leg ulcers (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
with lidocaine/prilocaine cream (EMLA) as a topical
anaesthetic for the cleansing of venous leg ulcers. Acta
Dermato-Venereologica 1993;73(3):231–3.
Holm 1990 {published and unpublished data}
Holm J, Andren B, Grafford K. Pain control in the surgical
debridement of leg ulcers by the use of a topical lidocaine-
prilocaine cream EMLA. Acta Dermato-Venereologica 1990;
70(2):132–6.
Johnson 1992 {published and unpublished data}
Johnson CR, Repper J. A double blind placebo controlled
study of lidocaine /prilocaine cream (EMLA 5%) used as a
topical analgesic for cleansing and redressing of leg ulcers.
Astra Pain Control AB (Confidential Report ) 1992.
Lok 1999 {published and unpublished data}
∗ Lok C, Paul C, Amblard P, Bessis D, Debure C, Faivre B,
et al.EMLA cream as a topical anesthetic for the repeated
mechanical debridement of venous leg ulcers: a double
blind controlled study. Journal of American Academy of
Dermatology 1999;40(2):208–13.
Paul C, Humbert P, Denoueux JP, Guillot B, Amblard P,
Guilhou JJ, et al.EMLA cream as a topical anaesthetic for
the repeated mechanical debridement of venous leg ulcers.
7th Annual Meeting European Tissue Repair Society; 1997,
23-26 August; Koln, Germany. 1997.
Rosenthal 2001 {published and unpublished data}
Rosenthal D. Use of EMLA sterile cream in the management
of leg ulcers. In: Koren G editor(s). An eutectic mixture of
local anesthetics. Marcel Dekker, 1995:137–44.
Rosenthal D, et al.A double blind, placebo controlled study
of lidocaine/prilocaine cream (EMLA 5%) used as a topical
analgesia for mechanical debridement of leg ulcers. Personal
communication 1992.
∗ Rosenthal D, Murphy F, Gottschalk R, Baxter M, Lycka B,
Nevin K. Using a topical anaesthetic cream to reduce pain
during sharp debridement of chronic leg ulcers. Journal of
Wound Care 2001;10(1):503–5.
References to studies excluded from this review
Allen 1982 {published data only}
Allen S, Cooper J. The effect of an antibacterial on pain in
ulcerated legs. British Journal of Clinical Practice 1980;34
(10):284–5.
Alvarez 2004 {published data only}
Alvarez OM, Patel M, Booker J, Markowitz L. Effectiveness
of a biocellulose wound dressing for the treatment of chronic
venous leg ulcers: results of a single center randomised
study involving 24 patients. Wounds: a Compendium of
Clinical Research and Practice 2004;16:224–33.
Alvarez 2010 {unpublished data only}
Alvarez O, Patel M, Phillips T, Menzoian J, Brown Etris
M, Andriessen A. Prospective, randomized, controlled,
multi-center clinical trial of a biocellulose wound dressing
for the treatment of venous ulcers. EWMA Journal. 2010;
Vol. 10, issue 23:Abstract 5.
Alvarez O, Rogers R, Booker J, Patel M. Treatment of
painful skin ulcers with a biocellulose dressing containing
lidocaine. SAWC 2006; April 30 - May 3, 2006; San
Antonio, Texas. 2006.
Alvarez OM, Patel M, Booker J, Markowitz L. Effectiveness
of a biocellulose wound dressing for the treatment of chronic
venous leg ulcers: results of a single centre randomized
study involving 24 patients. Wounds 2004;16(7):224–33.
∗ Alvarez OM, Patel M, Menzoian J, Brown Etris M,
Phillips T. A randomized, multi-center, clinical trial of a
biocellulose wound dressing for the treatment of chronic
venous ulcers (as supplied 16 November 2011). Personal
Communication 2010.
Armstrong 1997 {published data only}
Armstrong SH, Ruckley CV. Use of a fibrous dressing in
exuding leg ulcers. Journal of Wound Care 1997;6(7):322–4.
Arnold 1994 {published data only}
Arnold TE, Stanley JC, Fellows EP, Moncada GA, Allen
R, Hutchinson JJ, et al.Prospective, multicenter study of
managing lower extremity venous ulcers. Annals of Vascular
Surgery 1994;8(4):356–62.
Back 1995 {published data only}
Back IN, Finlay I. The analgesic effect of topical opioids
on painful skin ulcers. Journal of Pain and Symptom
Management 1995;10(7):493.
Barghorn 1994 {published data only}
Barghorn A, Wagner G. Percutaneous anesthesia and leg
ulcer debridement. Phlebologie 1994;23(5):161h–3h.
Brandrup 1990 {published data only}
Brandrup F, Menne T, Agren M, Stromberg H, Holst R,
Frisen M. A randomized trial of two occlusive dressings
in the treatment of leg ulcers. Acta Dermato-Venereologica
1990;70(3):231–5.
Bruckner 2010 {published data only}
Bruckner M, Wild T, Schwarz C, Payrich M, Eberlein T.
Autolytic wound cleansing potential of different cellulose-
based dressings. EWMA Journal 2009;9(2):170, Abstract
P146.
∗ Wild T, Eberlein T, Andriessen A. Wound cleansing
efficacy of two cellulose-based dressings. Wounds UK 2010;
6(3):14–21.
Carneiro 2003 {published data only}
Carneiro PM, Nyawawa ET. Topical phenytoin versus Eusol
in the treatment of non malignant chronic ulcers. East
African Medical Journal 2003;80(3):124–9.
Culyer 1983 {published data only}
Culyer AJ, MacFie J, Wagstaff A. Cost effectiveness of foam
elastomer and gauze dressings in the management of open
perineal wounds. Social Science and Medicine 1983;17(15):
1047–53.
Enander Malmros 1990 {published data only}
Enander Malmros I, Nilsen T, Lillieborg S. Plasma
concentrations and analgesic effect of EMLA (Lidocaine/
Prilocaine) cream for the cleansing of leg ulcers. Acta
Dermato-Venereologica 1990;70(3):227–30.
Falabella 1998 {published data only}
Falabella AF, Carson P, Eaglstein WH, Falanga V. The safety
and efficacy of a proteolytic ointment in the treatment
17Topical agents or dressings for pain in venous leg ulcers (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
if chronic ulcers of the lower extremity. Journal of the
American Academy of Dermatology 1998;39(5):737–40.
Flanagan 2006 {published data only}
Flanagan M, Vogensen H, Haase L. Case series investigating
the experience of pain in patients with chronic venous leg
ulcers treated with a foam dressing releasing ibuprofen.
World Wide Wounds (http://www.worldwidewounds.com/
2006/april/Flanagan/Ibuprofen-Foam-Dressing.html)
2006.
Foster 1994 {published data only}
Foster AVM, Eaton C, McConville ME. Application of
Opsite film: a new and effective treatment of painful
diabetic neuropathy. Diabetic Medicine 1994;11:768–72.
Freidman 1984 {published data only}
Freidman SJ, Su WP. Management of leg ulcers with
hydrocolloid occlusive dressing. Archives of Dermatology
1984;120(10):1329–36.
Harcup 1986 {published data only}
Harcup JW, Saul PA. A study of the effect of cadexomer
iodine in the treatment of venous leg ulcers. British Journal
of Clinical Practice 1986;40(9):360–4.
Harvey 1985 {published data only}
Harvey SG, Gibson JR, Burke CA. L-cysteine, glycine and
dl-threonine in the treatment of hypostatic leg ulceration: a
placebo-controlled study. Pharmatherapeutica 1985;4(4):
227–30.
Holloway 1989 {published data only}
Holloway GA, Johnasen KH, Barnes RW, Pierce GE. Multi
center trial of cadexomer iodine to treat venous stasis ulcer.
Western Journal of Medicine 1989;151(1):35–9.
Holst 1998 {published data only}
Holst RG, Kristofferson A. Lidocaine-prilocaine cream
(EMLA cream) as a topical anaesthetic for the cleansing
of leg ulcers. The effect of length of application time..
European Journal of Dermatology 1998;8(4):245–7.
Hughes 1989 {published data only}
Hughes LE, Harding KG, Bale S, McPake B. Wound
management in the community - comparison of Lyofoam
and Melolin. Care Science and Practice 1989;7(2):64–7.
Jørgensen 2006 {published data only}
Jørgensen B, Friis GJ, Gottrup F. Pain and quality of life for
patients with venous leg ulcers: proof of concept of the
efficacy of Biatain-Ibu, a new pain reducing wound dressing.
Wound Repair and Regeneration 2006;14(3):233–9.
Klemp 1986 {published data only}
Klemp P, Ravnborg L, Staberg B. Pain reaction in patients
with venous leg ulcers during treatment with Trypure.
Ugeskrift for Laeger 1986;148(13):762–3.
Larsen 1997 {published data only}
Larsen AM, Andersen KE, Berg BK. A comparative study on
the effect and function of Comfeel Purilon versus Intrasite
gel on leg ulcers. New approaches to the management of
chronic wounds:EuropeanWoundManagement Association
Conference; 1997, 27-29 April; Milan, Italy. 1997.
Larsson-Stymne 1990 {published data only}
Larsson-Stymne B, Rostein A, Widman M. An open clinical
study on plasma concentrations of lidocaine and prilocaine
after application of EMLA 5% cream to leg ulcers. Clinical
Dermatology in the year 2000; 22-25 May; London.
London, 1990.
Laudanska 1988 {published data only}
Laudanska H, Gustavson B. In-patient treatment of chronic
varicose venous ulcers. A randomised controlled trial of
Cadexomer Iodine versus standard dressings. Journal of
International Medical Research 1988;16:428–35.
Lycka 1992 {published data only}
Lycka BAS. A new and effective topical anesthetic. Journal
Dermatologic Surgery and Oncology 1992;18(10):859–62.
MacGregor 1994 {published data only}
MacGregor KJ, Ahmedzai S, Riley J, Aulton ME, Patterson
LH. Symptomatic relief of excoriating skin conditions using
a topical thermoreversible gel. Palliative Medicine 1994;8
(1):76–7.
Mancini 2010 {published data only}
Mancini S, Menchinelli M, Baldoni G, Botta G.
Comparison of local anaesthesia for surgical debridement.
EWMA Journal 2010;10(2):226, Abstract P238.
Meaume 2008 {published data only}
Meaume S, Ourabah Z, Romanelli M, Manopulo R, De
Vathaire F, Salomon D, et al.Efficacy and tolerance of a
hydrocolloid dressing containing hyaluronic acid for the
treatment of leg ulcers of venous or mixed origin. Current
Medical Research and Opinion 2008;24(10):2729–39.
Mulligan 1986 {published data only}
Mulligan CM, Bragg AJ, O’Toole OB. A controlled
comparative trial of actisorb activated charcoal cloth
dressings in the community. British Journal of Clincal
Practice 1986;40(4):145–8.
Nowak 1996 {published data only}
Nowak A, Gwiezdzinski Z, Bowszyc J, Szarmach H,
Czabanowska J, Harding EF. A randomized controlled
parallel-group clinical trial of a new debriding agent in
the treatment of necrotic venous ulcers. Proceedings of
the 5th European Conference on Advances in Wound
Management; 1995, 21-24 November; Harrogate, UK.
Harrogate: Macmillan, 1996:190–3.
Ohlsen 1994 {published data only}
Ohlsen L, Grafford K, Evers H. EMLA cream as a topical
anaesthetic for ulcer debridement and simultaneous split-
skin grafting. European Journal of Plastic Surgery 1994;17:
277–82.
Ohlsson 1994 {published data only}
Ohlsson P, Larsson K, Lindhom C, Moller M. A cost
effectiveness study of leg ulcer treatment in primary care.
Scandanavian Journal of Primary Health Care 1994;12:
295–9.
Oluwatosin 2000 {published data only}
Oluwatosin OM, Olabanji JK, Oluwatosin OA, Tijani
LA, Onyechi HU. A comparison of topical honey and
18Topical agents or dressings for pain in venous leg ulcers (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
phenytoin in the treatment of chronic leg ulcers. African
Journal of Medicine and Medical Sciences 2000;29(1):31–4.
Peschen 1997 {published data only}
Peschen M, Hackenjos K, Wiek K, Schopf E, Vanscheidt
W. Lidocaine-prilocaine cream (EMLA (R)) as a topical
anaesthetic for CO2 laser debridement of venous leg ulcers.
Phlebology 1997;26(4):120–3.
Poglinano 2010 {published data only}
Polignano R, Terriaca P, Pavanelli A, Forma O, De Ponti I,
Sparavigna A. Evaluation of the efficacy of a cream with
purified omental lipids (P.O.L.) in the management of peri-
lesional skin in chronic vascular ulcers. Journal of Plastic
Dermatology 2010;6(3):235–44.
Romanelli 2008 {published data only}
Romanelli M, Dini V, Barbanerera S, Bertone MS, Brilli A,
De Lorenzo A. Improvement of treatment in patients with
venous leg ulcers by a new pain-reducing wound dressing
with hydrobalance. EWMA Journal 2008;8(2 Supp):286,
Abstract No. P366.
Romanelli 2010 {published data only}
Romanelli M, Dini V, Barbanera S, Bertone MS. Evaluation
of the efficacy and tolerability of a solution containing
propyl betaine and polihexanide for wound irrigation. Skin
Pharmacology and Physiology 2010;23(Suppl 1):41–4.
Shun 1983 {published data only}
Shun A, Ramsey-Stewart G. Human amnion in the
treatment of chronic ulceration of the legs. Medical Journal
of Australia 1983;2(6):279–83.
Sibbald 2006 {published data only}
Sibbald RG, Coutts P Fierheller M. Decreased chronic
(persistent) wound pain with a novel sustained release
ibuprofen foam dressing. Poster presented at European
Wound Management Association, Prague, Czech Republic.
2006.
Sibbald 2011 {published data only}
Sibbald RG, Coutts P, Woo KY. Reduction of bacterial
burden and pain in chronic wounds using a new
polyhexamethylene biguanide antimicrobial foam dressing-
clinical trial results. Advances in Skin and Wound Care 2011;
24(2):78–84.
Skog 1983 {published data only}
Skog E, Arnesjo B, Troeng T, Gjores JE, Bergljung
L, Gundersen J, et al.A randomized trial comparing
cadexomer iodine and standard treatment in the out-patient
management of chronic venous ulcers. British Journal of
Dermatology 1983;109(1):77–83.
Smith 1992 {published data only}
Smith JM, Dore CJ, Charlett A, Lewis JD. A randomised
trial of biofilm dressing for venous leg ulcers. Phlebology
1992;7(3):108–13.
Stacey 1999 {published data only}
Stacey MC, Wysocki SJ, Vandongen YK, Bunn C.
Urokinase-type plasminogen activator inhibition by
plasminogen activator inhibitor type 2 in chronic venous
ulcers. 9th European Conference on Advances in Wound
Management; 1999, 9-11 November; Harrogate UK.
Harrogate: Macmillan, 1999.
Twillman 1999 {published data only}
Twillman RK. Treatment of painful skin ulcers with topical
opioids. Journal of Pain and Symptom Management 1999;17
(4):289–92.
Vernassiere 2005 {published and unpublished data}
Vernassiere C, Cornet C, Trechot P, Alla F, Truchetet F,
Cuny JF, et al.Study to determine the efficacy of topical
morphine on painful chronic skin ulcers. Journal of Wound
Care 2005;14(6):289–93.
Wanger 1990 {published data only}
Wanger L, Eriksson G, Karlsson A. Analgesic effect and local
reactions of repeated application of EMLA ® (lidocaine
prilocaine cream for the cleansing of leg ulcers. Clinical
Dermatology in the year 2000; 22-25 May; London. 1990:
164.
Woo 2009 {published data only}
Woo KY, Coutts PM, Price P, Harding K, Sibbald RG.
A randomized crossover investigation of pain at dressing
change comparing 2 foam dressings. Advances in Skin and
Wound Care 2009;22(7):304–10.
References to studies awaiting assessment
Claeys 2011 {published data only}
Claeys A, Gaudy-Marqueste C, Pauly V, Pelletier F,
Truchetet F, Boye T, et al.Management of pain associated
with debridement of leg ulcers: a randomized, multicentre,
pilot study comparing nitrous oxide-oxygen mixture
inhalation and lidocaïne-prilocaïne cream. Journal of the
European Academy of Dermatology and Venereology 2011;25
(2):138–44.
Mosti 2010 {published data only}
Mosti G, Mattaliano V, Conte R, Abel M. Promotion of
healing, pain relief, tolerability and quality of life: results
of a prospective, controlled, randomized comparison study
with two wound dressings in out-patients with non-infected
leg ulcers. EWMA Journal. 2010; Vol. 10, issue 2:59,
Abstract 77.
Mosti G, Mattaliano V, Mantero M, Abel M. Prospective,
controlled, randomized comparison study of two various
wound dressing systems under compression. 79.170.40.55/
activahealthcare.co.uk/pdf/SX015.pdf (Accessed 21
November 2011).
Additional references
Abbott 1992
Abbott FV, Gray-Donald K, Sewitch MJ, Johnston CC,
Edgar L, Jeans ME. The prevalence of pain in hospitalized
patients and resolution over six months. Pain 1992;50(1):
15–28.
Bandolier Extra 2005
Bandolier Extra. Topical Analgesics: A review of reviews
and a bit of perspective. http://www.medicine.ox.ac.uk/
bandolier/Extraforbando/Topextra3.pdf 2005 (Accessed 25
November 2008).
19Topical agents or dressings for pain in venous leg ulcers (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Blanke 2003
Blanke W, Hallern BV. Sharp wound debridement in local
anaesthesia using EMLA cream: 6 years experience in 1084
patients. European Journal of Emergency Medicine 2003;10:
229–31.
Bradley 1999
Bradley M, Cullum N, Sheldon T. The debridement of
chronic wounds: a systematic review. Health Technology
Assessment 1999;3(17 Pt 1):1–65.
Briggs 2007
Briggs M, Flemming KA. Living with leg ulceration: a
synthesis of qualitative research. Journal of Advanced
Nursing 2007;59:319–28.
Callam 1985
Callam MJ, Ruckley CV, Harper DR, Dale JJ. Chronic
ulceration of the leg; extent of the problem and provision of
care. British Medical Journal 1985;290:1855–6.
Callam 1987
Callam MJ, Harper DR, Dale JJ, Ruckley CV. Chronic
ulcer of the leg: clinical history. British Medical Journal
1987;294(6584):1389–91.
Chase 1997
Chase SK, Melloni M, Savage A. A forever healing: the
lived experience of venous ulcer disease. Journal of Vascular
Nursing 1997;15(2):73–8.
Cleeland 1994
Cleeland CS, Ryan KM. Pain assessment: global use of the
Brief Pain Inventory. Annals of the Academy of Medicine
1994;23(2):129–38.
Dahl 1994
Dahl JB, Moiniche S, Kehlet H. Wound infiltration with
local anaesthetics for post operative pain relief. Acta
Anaesthesiologica Scandinavica 1994;38:7–14.
Deeks 1998
Deeks JJ. Odds ratios should be used only in case control
studies and logistic regression analyses. BMJ 1998;317:
1155–6.
Douglas 2001
Douglas V. Living with a chronic leg ulcer: an insight into
patients’ experiences and feelings. Journal of Wound Care
2001;10(9):355–60.
Dworkin 2008
Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland
CS, Farrar JT. Interpreting the clinical importance of
treatment outcomes in chronic pain clinical trials. Journal
of Pain 2008;9(2):105–21.
Ebbeskog 2001
Ebbeskog B, Ekman SL. Elderly persons’ experiences of
living with venous leg ulcer: living in a dialectal relationship
between freedom and imprisonment. Scandinavian Journal
of Caring Sciences 2001;15(3):235–43.
Eriksson 1992
Eriksson AS, Sinclair R, Cassuto J, Thomsen P. Influence
of lidocaine on leukocyte function in the surgical wound.
Anaesthesiology 1992;77:74–8.
Flock 2003
Flock P. Pilot study to determine the effectiveness of
diamorphine gel to control pressure ulcer pain. Journal of
Pain and Symptom Management 2003;25:547–54.
Franks 1994
Franks PJ, Moffatt CJ, Connolly M, Bosanquet N, Oldroyd
M, Greenhalgh RM, et al.Community leg ulcer clinics;
effect on quality of life. Phlebology 1994;9:83–6.
Gibson 1998
Gibson JME, Kenrick M. Pain and powerlessness; the
experience of living with peripheral vascular disease. Journal
of Advanced Nursing 1998;27:737–45.
Graham 2003
Graham I, Harrison MB, Nelson EA, Lorimer K, Fisher A.
Prevalence of lower-limb ulceration: a systematic review
of prevalence studies. Advances in Skin and Wound Care.
2003;16(6):305–16.
Hamer 1994
Hamer C, Cullum NA, Roe BH. Patients’ perceptions of
leg ulceration. Journal of Wound Care 1994;3:99–101.
Hermans 1993
Hermans MHE. Air exposure versus occlusion; advantages
and disadvantages. Journal of Wound Care 1993;2(6):362–5.
Higgins 2002
Higgins JPT, Thompson SG. Quantifying heterogeneity in
a meta-analysis. Statistics in Medicine 2002;21:1539–58.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327
(7414):557–60.
Higgins 2011
Higgins JPT, Altman DG, Sterne JAC on behalf of the
Cochrane Statistical Methods Group and the Cochrane
Bias Methods Group. Chapter 8: Assessing risk of
bias in included studies. In: Higgins JPT, Green S
(editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Hofman 1997
Hofman D, Ryan TJ, Arnold F, Cherry GW, Lindholm C,
Glynn C. Pain in venous leg ulcers. Journal of Wound Care
1997;6(5):222–4.
Hyde 1999
Hyde C, Ward B, Horsfall J, Winder G. Older women’s
experience of living with chronic leg ulceration.
International Journal of Nursing Practice 1999;5(4):189–98.
Hyland 1994
Hyland ME, Thomson B. Quality of life of leg ulcer
patients. Journal of Wound Care 1994;3(6):294–7.
Kannon 1995
Kannon GA, Garrett AB. Moist wound healing with
occlusive dressings. Dermatological Surgery 1995;21(7):
583–90.
20Topical agents or dressings for pain in venous leg ulcers (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lefebvre 2011
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching
for studies. In: Higgins JPT, Green S (editors). Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011). The Cochrane Collaboration,
2011. Available from www.cochrane-handbook.org 2011.
Lindholm 1993
Lindholm C, Bjellerup M, Christensen OB, Zederfeld B.
Quality of life in chronic leg ulcer patients. Acta Dermato-
Venereologica 1993;73(6):440–3.
Margolis 2000
Margolis DJ, Berlin JA, Strom BL. Which venous leg ulcers
will heal with limb compression bandages?. American
Journal of Medicine 2000;109(1):15–19.
Margolis 2004
Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. The
accuracy of venous leg ulcer prognostic models in a wound
care system. Wound Repair and Regeneration 2004;12:
163–8.
McQuay 1997
McQuay HJ, Moore RA, Eccleston C, Morley S, de C
Williams AC. Chapter 4 - Pain measurement, study design
and validity. A systematic review of outpatient services for
chronic pain control. Vol. 1, Health Technology Assessment
Report, 1997:11–29.
Moffatt 2002
Moffat C, Franks PJ, Hollinworth H. Understanding
wound pain and trauma: an international perspective.
European Wound Managememt Association Position Paper.
2002:2–7.
Nelzen 1994
Nelzen O, Bergqvist D, Lindhagen A. Venous and non
venous leg ulcers: clinical history and appearance in a
population study. British Journal of Surgery 1994;81:182–7.
Noonan 1998
Noonan L, Burge SM. Venous leg ulcers: is pain a problem?
. Phlebology 1998;13:14–9.
O’Brien 2000
O’Brien JF, Grace PA, Perry IJ, Burke PE. Prevalence and
aetiology of leg ulcers in Ireland. Irish Journal of Medicine
2000;169(2):110–3.
Pedersen 1996
Pedersen JL, Callesen S, Moiniche S, Kehlet H. Analgesic
and anti-inflammatory effects of lignocaine-prilocaine
(EMLA) cream in human burn injury. British Journal of
Anaesthesia 1996;76:806–10.
Phillips 1994
Phillips T, Stanton B, Provan A, Lew R. A study of the
impact of leg ulcers on quality of life: Financial, social and
psychologic implications. Journal of American Academy of
Dermatology 1994;31(1):49–53.
RevMan 2011
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). 5.1. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2011.
Ribeiro 2004
Ribeiro MD, Joel SP, Zeppetella G. The bioavailability of
morphine applied topically to cutaneous ulcers. Journal of
Pain and Symptom Management 2004;27(5):434–9.
Richardson 2010
Richardson C, Upton D. A discussion of the potential
mechanisms for wound dressings’ apparent analgesic effects.
Journal of Wound Care 2010;19(10):424–30.
Schulz 2010
Schulz KF, Altman DG, Moher, D, for the CONSORT
Group 2010. CONSORT 2010 Statement: updated
guidelines for reporting parallel group randomised trials.
Annals of Internal Medicine 2010;152(11):1–8.
Seeley 1994
Seeley JE. Use of a transparent film dressing for pain control.
Proceedings of the 3rd European Conference on Advances
in Wounds Management. London: Macmillan Magazines,
1994:57.
SIGN 2012
Scottish Intercollegiate Guidelines Network (SIGN). Search
filters. http://www.sign.ac.uk/methodology/filters.html#
random (Accessed 23 August 2012).
Steed 1996
Steed DL, Donohoe D, Webster MW, Lindsley L. Effect of
extensive debridement and treatment on healing of diabetic
foot ulcers. Journal of the American College of Surgeons 1996;
183:61–4.
Stein 1995
Stein C. Morphine - A local analgesic. International
Association for the Study of Pain Clinical Updates 1995;3(1):
1–8.
Thomas 1989
Thomas S. Pain and wound management. Community
Outlook 1989;July:11–15.
Vanscheidt 2001
Vanscheidt W, Lillieborg S. EMLA anaesthetic cream for
sharp debridement: a review of the clinical evidence for
analgesic efficacy and tolerability. European Journal of
Dermatology 2001;11(2):90–6.
Walshe 1995
Walshe C. Living with a venous ulcer: a descriptive study of
patients experiences. Journal of Advanced Nursing 1995;22
(6):1092–100.
Zeppetella 2004
Zeppetella G. Topical opioids for painful skin ulcers; do
they work?. European Journal Palliative Care 2004;11(3):
93–6.
∗ Indicates the major publication for the study
21Topical agents or dressings for pain in venous leg ulcers (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agrifoglio 2000
Methods Multicentred RCT (seven centres in Italy).
Participants 110 people with venous leg ulcers.
Exclusion criteria: participants were excluded from the trial if diabetes or infection was
noted, or if the area of the ulcer was greater than 50 cm²
Fifty-four participants were randomised to EMLA and 56 to placebo
Interventions 1. EMLA: % not stated (2.5g per 10 cm² to a maximum 10g).
2. Placebo cream.
EMLA (2.5 g per 10 cm² ) was applied as a cream for 30 to 45 minutes prior to debride-
ment of the wound. ’Cling film’ was used to occlude the ulcer during the application
time
The constituents of the placebo cream were not provided.
The debridement was performed using a curette, scissors, lancets and forceps
Baseline pain scores were not recorded.
Outcomes Pain at debridement was measured by a VAS after debridement.
The difficulty of performing the debridement was also explored by means of a physician-
rated 3-point scale
Notes Supported by Astra Pain Control AB.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The study was a randomised, dou-
ble-masked, placebo-controlled trial”
Comment: No methods for generation of
the randomisation sequence reported
Allocation concealment (selection bias) Unclear risk Quote: “The study was a randomised, dou-
ble-masked, placebo-controlled trial”
Comment: Procedure for participant allo-
cation to study groups not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Described as double-masked,
placebo-controlled. Assume participants
and personnel were blind to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: As it was a double-masked,
placebo-controlled trial, outcome assess-
ment (participant reported pain) would be
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Agrifoglio 2000 (Continued)
blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Sixty patients per group were
planned for inclusion in the study, this sam-
ple size including a 20% increase to account
for drop-outs.”
Quote: “Fifty-four patients were ran-
domised to treatment with EMLA and 56
to placebo cream.”
Comment: Although no statement on
numbers of patients completing/withdraw-
ing from treatment, all patients randomised
represented in results tables
Selective reporting (reporting bias) Low risk Comment: No protocol available but arti-
cle title, study aims, treatment investigated
and outcomes reported indicative of non-
selective reporting
Other bias Low risk Comment: No other potential sources of
bias evident.
Arapoglou 2011
Methods Multicentred RCT conducted in 12 countries (184 centres).
Setting: inpatients and outpatients
Participants 853 inpatients and outpatients with painful exuding wounds of various aetiologies were
originally recruited (group 1 n = 189 with venous leg ulcers, group 2 n = 159 with venous
leg ulcers). The trialists report data for 688 participants belonging to wound aetiology
categories comprising more than 25 patients (venous leg ulcers, arterial ulcers, mixed
aetiology, vasculitis and traumatic)
People were excluded if they had hypersensitivity to acetylsalicylic acid or other non-
steriodal anti-inflammatories (NSAIDs), if the trial ulcer was infected, discoloured, or
odorous, if they had pressure ulcers of grade I, III or IV (according to NPUAP classifica-
tion) or a diabetic foot ulcer foot ulcer grade 3, 4 ,5 (according to Wagner classification)
(reported in Domenech 2008)
Interventions 1. Foam dressing containing 0.5 mg/cm2 ibuprofen homogeneously dispersed (Biatain
Ibu)
2. Local best practice - standard dressings at the investigator site used for painful exuding
wounds
Mean (SD) treatment duration was 7(±2) days.
All concomitant treatments were allowed, although patients were asked not to alter the
dosage of any pain-relieving medication
Pain was assessed twice daily using a 5-point scale (0 = no relief, 1 = slight, 2 = moderate,
3 = marked, 4 = complete pain relief )
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Arapoglou 2011 (Continued)
Outcomes Pain relief was evaluated on a 5-point scale (0 = no pain, 1 = slight, 2 = moderate, 3 =
marked, 4 = complete relief )
Pain intensity was assessed using an 11-point scale (0 = no pain, 10 = worse pain ever)
The trial authors reported pain outcomes, categorised using TOTPAR (total pain relief )
and SPID (summed pain intensity difference), as:
Proportionof patientswith >50%pain relief score fromday 1 to day 5 (TOTPARD5>50% )
.
Proportion of patients with > 50% pain relief daily.
Proportion of patients with > 50% reduction from baseline of pain intensity on day 5
(SPIDD5>50%).
Notes Only reports outcomes for wound aetiology categories with >25 patients (688 patients)
Other outcomes evaluated in the secondary reference by Domenech 2008 (quality of
life, adverse events, the overall pain-relieving effect of the dressing, changes in the intake
of pain-relieving medicine, condition of the peri-ulcer skin, leakage, and dressing time
taken) were not reported
Pain outcome data were available separately for venous leg ulcers (and other wound
aetiologies)
As outcome data for the venous leg ulcer participants alone was not reported by
Domenech 2008 report, we have used the venous leg ulcer participant data presented by
Arapoglou 2011 for our analysis.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Using a computer-generated list
in sealed envelopes, patients were ran-
domly assigned to either treatmentwith the
ibuprofen-releasing foam (test) dressing or
local best practice.”
Comment: reported in secondary reference
(Domenech 2008).
Allocation concealment (selection bias) Unclear risk Quote: “Using a computer-generated list
in sealed envelopes, patients were ran-
domly assigned to either treatmentwith the
ibuprofen-releasing foam (test) dressing or
local best practice.”
Comment: envelopes not described as
opaque or sequentially numbered. Re-
ported in secondary reference (Domenech
2008)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “As it was an open study design,
there was the inherent possibility of treat-
ment bias frompatients or study personnel.
”
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Arapoglou 2011 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “As it was an open study design,
there was the inherent possibility of treat-
ment bias frompatients or study personnel.
”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “The analyses were performed on
the intention-to-treat (ITT) population in
accordance with the pre-specified statisti-
cal plan.” (Reported in secondary reference
(Domenech 2008))
Comment: numbers of patients not com-
pleting study and reasons for both
groups reported in secondary reference
(Domenech 2008). Low withdrawal rate
(Group 1: 11%; Group 2: 8%). All patients
randomised included in final analysis (Flow
chart presented in Domenech 2008)
Selective reporting (reporting bias) Low risk Comment: No protocol available but arti-
cle title, study aims, treatment investigated
and outcomes reported indicative of non-
selective reporting
Other bias Low risk Comment: No other potential sources of
bias evident.
Gottrup 2008
Methods Multicentred RCT. Setting not reported
Performance and ascertainment biases were minimised by the trial being double-blind.
Participants 122 people with leg ulcers
People were excluded if they had a contraindication to NSAIDs, had infected wounds or
had painful ulcers that had been resistant to analgesic treatment over the last six months.
62 were randomised to receive a foam dressing containing ibuprofen (Biatain-Ibu,
Colopolast A/S, Denmark) and 62 to receive an identical foam dressing without ibupro-
fen (Biatain Non-Adhesive, Coloplast A/S, Denmark)
Interventions 1. Foam dressing containing ibuprofen (Biatain-Ibu, Colopolast A/S, Denmark).
2. Identical foam dressing without ibuprofen (Biatain Non-Adhesive, Coloplast A/S,
Denmark)
Outcomes Persistent pain relief was assessed on a 5-point scale (no relief, slight relief, moderate
relief, lots of relief, complete relief ), that was then categorised to pain relief, yes (slight,
moderate, lots, complete) or no pain relief in the final analysis
Proportion of ulcers healed.
Notes Sponsored by Coloplast A/S.
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Gottrup 2008 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “This randomised, controlled dou-
ble-blind, parallel-group, multicenter, and
multinational clinical investigation . . .”
Nomethods for generation of the randomi-
sation sequence reported
Allocation concealment (selection bias) Unclear risk Quote: “Randomisation in closed en-
velopes took place after inclusion and be-
fore study initiation.”
Comment: envelopes not described as
opaque or sequentially numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Study personnel and patients were
blind to treatment from days 1 to 42 (dou-
ble blind).”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Persistent (relief and intensity) and
temporary pain (dressing change related)
were assessed at days 1-5 and at days 43-
47.”
Comment: As participants were blind to
treatment, outcome assessment (partici-
pant reported pain) would be blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All data analysis was performed.
..on the intention-to-treat (ITT) popula-
tion.”
Comment: Numbers withdrawing and rea-
sons reported. Numbers and reasons bal-
anced across groups. Drop-out rate 23%
Selective reporting (reporting bias) Low risk Comment: No protocol available but arti-
cle title, study aims, treatment investigated
and outcomes reported indicative of non-
selective reporting
Other bias Low risk Comment: No other potential sources of
bias evident.
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Hansson 1993
Methods Single-centred, open, RCT (Sweden).
Setting: dermatology and surgery departments of one hospital in Sweden
Participants 43 people with venous leg ulcers.
Exclusion criteriawere: ulcer > 50 cm²; history of sensitivity to local anaesthetics; previous
treatment with EMLA; ongoing antibiotics or proteolytic enzyme treatment
Twenty-two participants received EMLA, and, in the control group 21 participants did
not receive either a “vehicle cream” (placebo) or anaesthesia
Interventions 1. EMLA 5%.
2. No treatment.
Each participant underwent eight successive debridements separated by a period of two
to nine days
The debridement was performed using a curette, scissors, or a swab
Outcomes Pain ondebridementwasmeasuredusing a visual analogue scale (VAS) after the procedure
The occurrence of post-cleansing pain (up to four hours) was noted at each debridement
session
Additional data were collected about local reactions to the cream (patient-rated); reduc-
tion in necrotic tissue and ulcer size (using acetate tracing)
Number of ulcers healed at the end of the trial.
Notes Supported by Astra Pain Control AB.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The study had an open ran-
domised parallel-group design with a con-
trol group”
Nomethods for generation of the randomi-
sation sequence reported
Allocation concealment (selection bias) Unclear risk Quote: “A sealed envelope individual to
each patient, containing information on al-
location to EMLA allocation or control,
was opened immediately before the first
treatment.”
Comment: envelopes not described as
opaque or sequentially numbered
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: Trial described as open.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: Trial described as open.
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Hansson 1993 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: No statement on whether anal-
ysis was ITT or per-protocol, but numbers
withdrawing from study arms low (< 1%)
Selective reporting (reporting bias) Low risk Comment: No protocol available but arti-
cle title, study aims, treatment investigated
and outcomes reported indicative of non-
selective reporting
Other bias Unclear risk Comment: No other potential sources of
bias evident.
Holm 1990
Methods Double-blind RCT (Sweden).
Setting: outpatient department.
The trial was described as a two-part study, first an open part and then a double-blind
placebo controlled part
Participants 30 patients (19 had venous leg ulcers and 11 arterial ulcers)
50 participants initially took part in the open phase (all received EMLA 5%), of which
30 then took part in the double-blind (RCT) phase. The trialists do not report at what
point randomisation took place or why only 30 were included in the RCT
No specific inclusion or exclusion criteria were reported.
Interventions 1. EMLA 5%.
2. Placebo cream.
The double-blind controlled trial evaluated a 30-minute exposure to placebo or active
cream
Both creams were identically packaged and applied in the same way, i.e. as a thick layer
of cream under an occlusive dressing (Glad, Germany) for 30 minutes
The ulcer was debrided using tweezers, scissors and a curette
The treatments were randomised and stratified for types of ulcer (venous or arterial) but
not for concomitant diabetes
Outcomes Debridement pain was assessed during the procedure using a 0 to 100 VAS and a 4-
point verbal rating scale
Local reactions to the cream were examined by asking participants about itching or
burning, and observations of the area after removal of the cream
The data for the venous ulcer participants was available separately
Notes Supported by Astra Pain Control AB.
Risk of bias
Bias Authors’ judgement Support for judgement
28Topical agents or dressings for pain in venous leg ulcers (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Holm 1990 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “The treatments were randomised
and stratified for type of ulcer (venous or
arterial) but not for concomitant diabetes.
”
Comment: No methods for generation of
the randomisation sequence reported
Allocation concealment (selection bias) Unclear risk Quote: “In the double-blind part, patients
were treated with either EMLA cream or
placebo”
Comment: Procedure for concealment of
participant allocation to study groups not
reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Trial described as double-blind.
Assume participants and personnel were
blind to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: As participants were blind to
treatment, outcome assessment (partici-
pant reported pain) would be blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: Single-dose study. One patient
in the control arm missing VAS pain score
Selective reporting (reporting bias) Low risk Comment: No protocol available but arti-
cle title, study aims, treatment investigated
and outcomes reported indicative of non-
selective reporting
Other bias High risk Quote: “In this study the randomisation
protocol did not take account of diabetes.
This resulted in an imbalance of patients
with diabetes in the arterial ulcer group
with themajority of diabetics in the placebo
group.”
Quote: “This is probably the explanation
why we could not find any significant ef-
fect of EMLA in the arterial ulcer group,
since all the placebo group happened to be
diabetics.”
Comment: Groups may not have been bal-
anced for prognostic factors at baseline
29Topical agents or dressings for pain in venous leg ulcers (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Johnson 1992
Methods Double-blind, parallel group, placebo-controlled, randomised trial conducted in four
centres in Scotland, UK
Participants 41 people with venous leg ulcers of which 7 had arterial ulcers; 5 had mixed aetiology
ulcers and 1 had a vasculitic ulcer
Exclusion criteriawere: ulcer > 50 cm²; history of sensitivity to local anaesthetics; diabetes;
anyone whom the investigators deemed unsuitable due to pathological processes or
anatomical variations
People were only included in the trial if they had previously experienced pain during
wound cleansing of greater than 25 mm (measured using a VAS) (Unpublished trial
provided by Astra Zeneca)
Interventions 1. EMLA 5%.
2. Placebo cream.
EMLA (5%) cream was applied for 30 minutes prior to debridement of the wound and
covered with ’cling film’
Participants received either EMLA (5%) or placebo packaged in identical aluminium
tubes
Outcomes Three pain assessments were recorded by means of a VAS:
1. pain during ulcer cleansing;
2. pain on re-dressing the ulcer;
3. overall pain score.
The first two VAS scores were participant-generated, whilst the third was performed by
the person performing the cleansing and re-dressing
Local reactions were assessed after removal of the cream bymeans of a symptom checklist
(e.g. burning, itching) and evidence of skin reaction
The descriptions of ulcer cleansing were listed as wiping, dabbing, irrigating, removal of
debris, cutting, scraping, and scraping until bleeding
Notes Supported by Astra Pain Control AB.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The study was designed as a mul-
ticentre trial, which was double-blind, par-
allel group, placebo controlled and ran-
domised in blocks of two,”
Nomethods for generation of the randomi-
sation sequence reported
Allocation concealment (selection bias) Unclear risk Quote: “The patients were randomly allo-
cated to receive either EMLA or placebo
before the cleansing and re-dressing of their
leg ulcer.”
Comment: Procedure for concealment of
participant allocation to study groups not
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Johnson 1992 (Continued)
reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Trial described as double-blind.
Assume participants and personnel were
blind to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: As participants were blind to
treatment, outcome assessment (partici-
pant reported pain) would be blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Fifty-four patients were included
in the study. Of these 52 patients were el-
igible for both efficacy and safety analysis
and 2 were eligible only for safety analysis
as a result of insufficient pain on the com-
prehension VAS.”
Selective reporting (reporting bias) Low risk Comment: Clinical report available. No se-
lective reporting evident
Other bias Low risk Comment: No other potential sources of
bias evident.
Lok 1999
Methods Multicentred RCT, double-blind, placebo-controlled design (nine centres in France)
Setting: departments of dermatology and phlebology
Participants 69 people with venous leg ulcers.
Inclusion criteria were: ulcer area 5 -50 cm²; necrotic tissue over 50% of the ulcer; ulcer
judged to require at least 3 debridement sessions in the first week; no previous treatment
with EMLA
Thirty-six participants received EMLA cream and 33 received placebo
Interventions 1. EMLA 5%.
2. Placebo cream.
A thick layer of cream was administered to the wound and covered with ’cling film’ for
30 to 45 minutes
Standardised oral analgesia was administered one hour before treatment
Debridement involved the use of curette and scissors.
All participants received the treatment prior to debridement with a maximum of up to
15 treatments
Outcomes Pain after debridement was measured using a VAS and the median number of debride-
ments required to achieve a clean ulcer was reported
Local reactions were assessed and adverse events noted.
31Topical agents or dressings for pain in venous leg ulcers (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lok 1999 (Continued)
Notes The trial is limited by the length of follow-up, since only 30% of the control group
achieved a clean ulcer by the end of the trial
Median number of debridements to achieve a clean ulcer:
EMLA: 11.5, Control: ”more than 15“.
Number of participants with a clean ulcer at the end of the study:
EMLA: 24 (66.7%) Control: 11 (33.3%).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: The primary objective of this ran-
domised, double-blind, placebo-controlled
study was to assess the effect of EMLA
cream on the number of mechanical de-
bridement sessions required to obtain a
clean ulcer.”
Comment: No methods for generation of
the randomisation sequence reported
Allocation concealment (selection bias) Unclear risk Comment: Procedure for concealment of
participant allocation to study groups not
reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Trial described as double-blind.
Assume participants and personnel were
blind to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: As participants were blind to
treatment, outcome assessment (partici-
pant reported pain) would be blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: No statement on numbers
of patients completing/withdrawing from
treatment. No statement on whether anal-
ysis was ITT or per-protocol
Selective reporting (reporting bias) Low risk Comment: No protocol available but arti-
cle title, study aims, treatment investigated
and outcomes reported indicative of non
selective reporting
Other bias Low risk Comment: No other potential sources of
bias evident.
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Rosenthal 2001
Methods Multicentred, double-blind, placebo-controlled, RCT (four centres in Canada)
Setting: dermatology clinics.
Participants 101 people with leg ulcers - 61 had venous leg ulcers.
All participants had previously experienced pain from leg ulcer debridement. People with
diabetes, large ulcers ( more than 50 cm²) or a history of allergy were excluded
51 were randomised to receive EMLA cream and 50 to receive placebo
Interventions 1. EMLA 5%.
2. Placebo cream.
A thick layer of cream was applied for approximately 30 minutes (range 25-37 minutes)
and covered with an occlusive dressing (plastic wrap)
Debridement involved the use of sharp curette, scissors, forceps or scalpel blade
Outcomes After cream removal, participants rated the severity of local reactions on a 4-point scale
(none, mild, moderate,severe)
After debridement, participants were asked to assess the degree of pain using a VAS
Notes Supported by Astra Pain Control AB.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “This was a randomised, double-
blind, parallel-group, placebo controlled,
multicenter trial.”
Cooment: No methods for generation of
the randomisation sequence reported
Allocation concealment (selection bias) Unclear risk Comment: Procedure for concealment of
participant allocation to study groups not
reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Trial described as double-blind.
Assume participants and personnel were
blind to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: As participants were blind to
treatment, outcome assessment (partici-
pant reported pain) would be blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “No data were excluded from the
analysis.”
Comment: Single-dose study so no with-
drawals would be anticipated
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Rosenthal 2001 (Continued)
Selective reporting (reporting bias) Low risk Comment: No protocol available but arti-
cle title, study aims, treatment investigated
and outcomes reported indicative of non-
selective reporting
Other bias Unclear risk Comment: No other potential sources of
bias evident.
Abbreviations used:
< - less than
> - greater than
EMLA - Eutectic Mixture of Local Anaesthetics (Lidocaine/Prilocaine Cream)
ITT - Intention-to-Treat
RCT - Randomised controlled trial
SPID - Sum of Pain Intensity Differences
TOTPAR - Total ain relief achieved
VAS - Visual Analogue Scale
VRS - Verbal Rating Scale (none, mild, moderate, severe)
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Allen 1982 Sample comprised people with infected wounds.
Alvarez 2004 Agent not used for pain relief.
Alvarez 2010 Agent not used for relieving pain. Pain measured as a secondary outcome
Armstrong 1997 Agent not used for relieving pain. Pain measured as a secondary outcome
Arnold 1994 Agent not used for relieving pain. Pain measured as a secondary outcome
Back 1995 Letter reporting ongoing trial. Contacted authors- trial was abandoned due to poor recruitment from
centres
Barghorn 1994 Not a randomised controlled trial.
Brandrup 1990 Agent not used for pain relief. Pain measured as a secondary outcome
Bruckner 2010 Agent not used for relieving pain. Pain measured as a secondary outcome
Carneiro 2003 Sample population did not have venous leg ulcers - and primary aim healing, not pain
34Topical agents or dressings for pain in venous leg ulcers (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Culyer 1983 Sample population did not have venous leg ulcers.
Enander Malmros 1990 Outcome measure was plasma concentration, not pain.
Falabella 1998 Agent was not used for pain relief. Pain measured as a secondary outcome
Flanagan 2006 Case series.
Foster 1994 Sample population did not have venous leg ulcers. Participants had areas of diabetic neuropathic pain, but
no wound
Freidman 1984 Not a randomised controlled trial.
Harcup 1986 Agent was not used for pain relief. Pain measured as a secondary outcome
Harvey 1985 The agent was not used for pain relief, and pain measures were a secondary outcome
Holloway 1989 Agent not used to relieve pain. Pain reported as a secondary outcome
Holst 1998 Outcome measure was plasma concentration, not pain.
Hughes 1989 Sample population did not have venous leg ulcers.
Jørgensen 2006 Cross-over design.
Klemp 1986 Agent not used for relieving pain. Pain measured as a secondary outcome
Larsen 1997 Agent was not used for pain relief. Pain measured as a secondary outcome
Larsson-Stymne 1990 No pain data available.
Laudanska 1988 Agent was not used for pain relief. Pain measured as a secondary outcome
Lycka 1992 Not a randomised controlled trial.
MacGregor 1994 Sample comprised malignant ulcers. Contacted authors, no further work planned
Mancini 2010 Not a randomised controlled trial.
Meaume 2008 Agent not used for relieving pain. Pain measured as a secondary outcome
Mulligan 1986 Agent was not used for pain relief. Pain measured as a secondary outcome
Nowak 1996 Pain measured as a secondary outcome.
Ohlsen 1994 Not a randomised controlled trial.
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(Continued)
Ohlsson 1994 Agent not used for pain relief. Pain outcomes poorly reported
Oluwatosin 2000 Agent not used for relieving pain. Pain measured as a secondary outcome
Peschen 1997 Not a randomised controlled trial.
Poglinano 2010 Agent not used for relieving pain. Pain measured as a secondary outcome
Romanelli 2008 Pain measured as a secondary outcome.
Romanelli 2010 Agent not used for relieving pain. Pain measured as a secondary outcome
Shun 1983 Sample population did not have venous leg ulcers. Pain outcomes not reported
Sibbald 2006 Sample comprised people with different wound types. Data not available for venous leg ulcer participants
only
Sibbald 2011 Agent not used for relieving pain. Pain measured as a secondary outcome
Skog 1983 Sample population did not have venous leg ulcers.
Smith 1992 Agent was not used for pain relief. Pain measured as a secondary outcome
Stacey 1999 Pain outcome not reported.
Twillman 1999 Sample population did not have venous leg ulcers.
Vernassiere 2005 Sample comprised people with different wound types. Data not available for venous leg ulcer participants
only
Wanger 1990 Not a randomised controlled trial.
Woo 2009 Agent not used for relieving pain. Pain measured as a secondary outcome (at dressing change)
Characteristics of studies awaiting assessment [ordered by study ID]
Claeys 2011
Methods Randomised controlled trial.
Participants 41 people with venous, arterial or mixed leg ulcers.
Interventions Nitrous oxide oxygen mixture or lidocaine-prilocaine cream.
Outcomes Pain before and after debridement on VAS and VRS.
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Claeys 2011 (Continued)
Notes Contacted authors requesting results for VLU participants only. Awaiting reply
Mosti 2010
Methods Randomised controlled trial.
Participants Inclusion criteria unclear from abstract.
Interventions A hydrobalanced cellulose based dressing or a foam wound dressing with Ibuprofen
Outcomes Pain on VAS, quality of life, wound size reduction or healing time
Notes Contacted authors requesting results for VLU participants only. Awaiting reply
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D A T A A N D A N A L Y S E S
Comparison 1. EMLA compared with placebo or no anaesthesia
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain score at debridement 6 317 Mean Difference (IV, Random, 95% CI) -20.65 [-29.11, -12.
19]
2 Number of healed wounds 1 43 Odds Ratio (M-H, Fixed, 95% CI) 6.56 [0.70, 61.85]
3 Incidence of burning at removal
of cream
3 232 Odds Ratio (M-H, Fixed, 95% CI) 1.72 [0.74, 4.01]
4 Incidence of itching at removal
of cream
3 233 Odds Ratio (M-H, Fixed, 95% CI) 1.68 [0.64, 4.38]
Comparison 2. Ibuprofen foam dressing compared with foam dressing alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number participants
experiencing pain relief on the
first evening of treatment
1 122 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.98, 1.65]
2 Number of healed wounds 1 122 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.32, 2.26]
3 Number participants
experiencing adverse events
1 122 Odds Ratio (M-H, Fixed, 95% CI) 1.46 [0.52, 4.11]
Comparison 3. Ibuprofen foam dressing compared with local best practice
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number participants reporting
TOTPARD5>50%
1 348 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [1.24, 2.15]
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Analysis 1.1. Comparison 1 EMLA compared with placebo or no anaesthesia, Outcome 1 Pain score at
debridement.
Review: Topical agents or dressings for pain in venous leg ulcers
Comparison: 1 EMLA compared with placebo or no anaesthesia
Outcome: 1 Pain score at debridement
Study or subgroup EMLA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Holm 1990 10 22.5 (23.9) 9 71.7 (33.1) 7.9 % -49.20 [ -75.41, -22.99 ]
Rosenthal 2001 30 31.1 (27.6) 31 52.8 (34.9) 15.3 % -21.70 [ -37.46, -5.94 ]
Agrifoglio 2000 54 24.9 (25.5) 56 49.4 (30.3) 21.9 % -24.50 [ -34.95, -14.05 ]
Lok 1999 22 33.6 (20.7) 21 49.3 (28.1) 16.4 % -15.70 [ -30.51, -0.89 ]
Hansson 1993 22 9.3 (12) 21 31.5 (24.8) 20.1 % -22.20 [ -33.93, -10.47 ]
Johnson 1992 21 21.1 (19.8) 20 26.7 (22.8) 18.4 % -5.60 [ -18.70, 7.50 ]
Total (95% CI) 159 158 100.0 % -20.65 [ -29.11, -12.19 ]
Heterogeneity: Tau2 = 56.77; Chi2 = 10.62, df = 5 (P = 0.06); I2 =53%
Test for overall effect: Z = 4.78 (P < 0.00001)
Test for subgroup differences: Not applicable
-200 -100 0 100 200
Favours EMLA Favours Control
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Analysis 1.2. Comparison 1 EMLA compared with placebo or no anaesthesia, Outcome 2 Number of healed
wounds.
Review: Topical agents or dressings for pain in venous leg ulcers
Comparison: 1 EMLA compared with placebo or no anaesthesia
Outcome: 2 Number of healed wounds
Study or subgroup EMLA Control
Odds
Ratio(Non-
event) Weight
Odds
Ratio(Non-
event)
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hansson 1993 1/22 5/21 100.0 % 6.56 [ 0.70, 61.85 ]
Total (95% CI) 22 21 100.0 % 6.56 [ 0.70, 61.85 ]
Total events: 1 (EMLA), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours EMLA Favours Control
Analysis 1.3. Comparison 1 EMLA compared with placebo or no anaesthesia, Outcome 3 Incidence of
burning at removal of cream.
Review: Topical agents or dressings for pain in venous leg ulcers
Comparison: 1 EMLA compared with placebo or no anaesthesia
Outcome: 3 Incidence of burning at removal of cream
Study or subgroup EMLA Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Agrifoglio 2000 3/54 1/56 11.3 % 3.24 [ 0.33, 32.11 ]
Johnson 1992 0/27 1/26 18.2 % 0.31 [ 0.01, 7.94 ]
Lok 1999 16/36 10/33 70.5 % 1.84 [ 0.68, 4.96 ]
Total (95% CI) 117 115 100.0 % 1.72 [ 0.74, 4.01 ]
Total events: 19 (EMLA), 12 (Control)
Heterogeneity: Chi2 = 1.38, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours EMLA Favours Control
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Analysis 1.4. Comparison 1 EMLA compared with placebo or no anaesthesia, Outcome 4 Incidence of
itching at removal of cream.
Review: Topical agents or dressings for pain in venous leg ulcers
Comparison: 1 EMLA compared with placebo or no anaesthesia
Outcome: 4 Incidence of itching at removal of cream
Study or subgroup EMLA Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Agrifoglio 2000 3/54 3/56 1.04 [ 0.20, 5.39 ]
Johnson 1992 0/27 0/27 0.0 [ 0.0, 0.0 ]
Lok 1999 10/36 5/33 2.15 [ 0.65, 7.14 ]
Total (95% CI) 117 116 1.68 [ 0.64, 4.38 ]
Total events: 13 (EMLA), 8 (Control)
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours EMLA Favours Control
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Analysis 2.1. Comparison 2 Ibuprofen foam dressing compared with foam dressing alone, Outcome 1
Number participants experiencing pain relief on the first evening of treatment.
Review: Topical agents or dressings for pain in venous leg ulcers
Comparison: 2 Ibuprofen foam dressing compared with foam dressing alone
Outcome: 1 Number participants experiencing pain relief on the first evening of treatment
Study or subgroup
Ibuprofen
foam
dressings
Foam dressing
without
ibuprofen Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gottrup 2008 46/62 35/60 100.0 % 1.27 [ 0.98, 1.65 ]
Total (95% CI) 62 60 100.0 % 1.27 [ 0.98, 1.65 ]
Total events: 46 (Ibuprofen foam dressings), 35 (Foam dressing without ibuprofen)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours non-ibu foam dressings Favours ibuprofen foam dressings
Analysis 2.2. Comparison 2 Ibuprofen foam dressing compared with foam dressing alone, Outcome 2
Number of healed wounds.
Review: Topical agents or dressings for pain in venous leg ulcers
Comparison: 2 Ibuprofen foam dressing compared with foam dressing alone
Outcome: 2 Number of healed wounds
Study or subgroup
Ibuprofen
foam
dressings
Foam dressing
without
ibuprofen Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gottrup 2008 9/62 10/60 100.0 % 0.85 [ 0.32, 2.26 ]
Total (95% CI) 62 60 100.0 % 0.85 [ 0.32, 2.26 ]
Total events: 9 (Ibuprofen foam dressings), 10 (Foam dressing without ibuprofen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours non-ibu foam dressings Favours ibuprofen foam dressings
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Analysis 2.3. Comparison 2 Ibuprofen foam dressing compared with foam dressing alone, Outcome 3
Number participants experiencing adverse events.
Review: Topical agents or dressings for pain in venous leg ulcers
Comparison: 2 Ibuprofen foam dressing compared with foam dressing alone
Outcome: 3 Number participants experiencing adverse events
Study or subgroup
Ibuprofen
foam
dressings
Foam dressing
without
ibuprofen Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gottrup 2008 10/62 7/60 100.0 % 1.46 [ 0.52, 4.11 ]
Total (95% CI) 62 60 100.0 % 1.46 [ 0.52, 4.11 ]
Total events: 10 (Ibuprofen foam dressings), 7 (Foam dressing without ibuprofen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours non-ibu foam dressings Favours ibuprofen foam dressings
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Analysis 3.1. Comparison 3 Ibuprofen foam dressing compared with local best practice, Outcome 1
Number participants reporting TOTPARD5>50%.
Review: Topical agents or dressings for pain in venous leg ulcers
Comparison: 3 Ibuprofen foam dressing compared with local best practice
Outcome: 1 Number participants reporting TOTPARD5>50%
Study or subgroup Ibuprofen dressings Best practice Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arapoglou 2011 93/189 48/159 100.0 % 1.63 [ 1.24, 2.15 ]
Total (95% CI) 189 159 100.0 % 1.63 [ 1.24, 2.15 ]
Total events: 93 (Ibuprofen dressings), 48 (Best practice)
Heterogeneity: not applicable
Test for overall effect: Z = 3.45 (P = 0.00055)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours best practice Favours Ibuprofen dressings
A D D I T I O N A L T A B L E S
Table 1. Comparison of EMLA intervention studies for clinical heterogeneity
Rosenthal 2001 Agrifoglio 2000 Lok 1999 Hansson 1993 Johnson 1992 Holm 1990
Venous ulcers (from
a mixed sample).
Venous ulcers. Venous ulcers. Venous ulcers. Venous ulcers (from
a mixed sample).
Venous ulcers (from
a mixed sample).
Dermatology
centres in Canada.
Vascular surgery
centres in Italy.
Dermatology
centres in France.
Dermatology
and surgical centres
in Sweden.
Health centres in
Scotland.
Surgical centre in
Sweden.
In-
cluded only patients
with previous expe-
rience of painful de-
bridement
All ulcers
had previously been
debrided.
Previous experience
of debridement not
stated.
Previous experience
of debridement not
stated.
In-
cluded only patients
with previous expe-
rience of painful de-
bridement
Previous experience
of debridement not
stated.
Diabetes excluded. Diabetes excluded. Not clear re dia-
betes.
Not clear re dia-
betes.
Diabetes excluded. Not clear re dia-
betes.
Ulcers > 50 cm2 ex-
cluded.
Ulcers > 50 cm2 ex-
cluded.
Ulcers > 50 cm2 ex-
cluded.
Ulcers > 50 cm2 ex-
cluded.
Ulcers > 50 cm2 ex-
cluded.
Not clear.
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Table 1. Comparison of EMLA intervention studies for clinical heterogeneity (Continued)
No concomitant
analgesia given.
No concomitant
analgesia given.
Concomitant anal-
gesia given.
No concomitant
analgesia given.
No concomitant
analgesia given.
No concomitant
analgesia given.
EMLA 5% for 30
minutes.
EMLA for 30 min-
utes.
EMLA 5% for 30
minutes.
EMLA 5% for 30
minutes.
EMLA 5% for 30
minutes.
EMLA 5% for 30
minutes.
Sharp debridement
with curette, forceps
and scissors.
Sharp debridement
with curette, forceps
and scissors.
Sharp debridement
with curette, forceps
and scissors.
Sharp debridement
with curette, forceps
and scissors.
All forms of ulcer
cleansing.
Sharp debridement
with curette, forceps
and scissors.
VAS after debride-
ment.
VAS after debride-
ment.
VAS after debride-
ment.
VAS after debride-
ment.
VAS after debride-
ment.
VAS during
debridement.
A P P E N D I C E S
Appendix 1. Search strategy for the second review update 2010
Search methods for identification of studies
Electronic searches
For this second update we searched the following electronic databases:
Cochrane Wounds Group Specialised Register (Searched 16/12/09)
The Cochrane Central Register of Controlled Trials (CENTRAL) - The Cochrane Library 2009 Issue 4
Ovid MEDLINE - 1950 to November Week 3 2009
Ovid MEDLINE - In-Process & Other Non-Indexed Citations (Searched 16/12/09)
Ovid EMBASE - 1980 to 2009 Week 50
EBSCO CINAHL - 1982 to December 16 2009
The following strategy was used to search The Cochrane Central Register of Controlled Trials (CENTRAL):
#1 MeSH descriptor Analgesia explode all trees
#2 MeSH descriptor Analgesics explode all trees
#3 MeSH descriptor Capsaicin explode all trees
#4 capsaicin:ti,ab,kw
#5 MeSH descriptor Analgesics, Opioid explode all trees
#6 opioid:ti,ab,kw
#7 MeSH descriptor Anti-Inflammatory Agents, Non-Steroidal explode all trees
#8 (non NEXT steroidal NEXT anti-inflammator* or NSAID*):ti,ab,kw
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
#10 MeSH descriptor Administration, Topical explode all trees
#11 topical or local:ti,ab,kw
#12 (#10 OR #11)
#13 (#9 AND #12)
#14 MeSH descriptor Anesthetics, Local explode all trees
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#15 ((topical or local) NEAR/3 (anaesthe* or anesthe*)):ti,ab,kw
#16 ((topical or local) NEAR/3 analgesi*):ti,ab,kw
#17 (#13 OR #14 OR #15 OR #16)
#18 MeSH descriptor Bandages explode all trees
#19 MeSH descriptor Hydrogels explode all trees
#20 MeSH descriptor Alginates explode all trees
#21 (dressing* or hydrocolloid* or alginate* or hydrogel* or “foam” or “bead” or “film” or “films” or tulle or gauze or non-adherent or
“non adherent”):ti,ab,kw
#22 MeSH descriptor Ointments explode all trees
#23 (ointment* or “cream” or “creams” or “gel” or “gels”):ti,ab,kw
#24 (#18 OR #19 OR #20 OR #21 OR #22 OR #23)
#25 MeSH descriptor Pain explode all trees
#26 pain*:ti,ab,kw
#27 (#25 OR #26)
#28 (#24 AND #27)
#29 (#17 OR #28)
#30 MeSH descriptor Leg Ulcer explode all trees
#31 ((varicose NEXT ulcer*) or (venous NEXT ulcer*) or (leg NEXT ulcer*) or (foot NEXT ulcer*) or (stasis NEXT ulcer*)):ti,ab,kw
#32 (#30 OR #31)
#33 (#29 AND #32)
The search strategies for Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL can be found in Appendix 2, Appendix 3 and
Appendix 4 respectively. TheOvidMEDLINE search was combined with the Cochrane Highly Sensitive Search Strategy for identifying
randomised trials in MEDLINE: sensitivity- and precision-maximizing version (2008 revision); Ovid format. The EMBASE and
CINAHL searches were combined with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN).
Searching other resources
Six additional records were identified from recent conference proceedings (European Wound Management Association, Lisbon 2008),
and other studies known to the review authors from reading reference lists and discussions with researchers in the field.
Appendix 2. Ovid MEDLINE search strategy
1 exp Analgesia/
2 exp Analgesics/
3 exp Capsaicin/
4 capsaicin.ti,ab.
5 exp Analgesics, Opioid/
6 opioid$.ti,ab.
7 exp Anti-Inflammatory Agents, Non-Steroidal/
8 (non steroidal anti-inflammator$ or NSAID$).ti,ab.
9 or/1-8
10 exp Administration, Topical/
11 (topical or local).ti,ab.
12 or/10-11
13 9 and 12
14 exp Anesthetics, Local/
15 ((topical or local) adj3 (anaesthe$ or anesthe$)).ti,ab.
16 ((topical or local) adj3 analges$).ti,ab.
17 or/13-16
18 exp Bandages/
19 exp Hydrogels/
20 exp Alginates/
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21 (dressing$ or hydrocolloid$ or alginate$ or hydrogel$ or foam or bead or film or films or tulle or gauze or non-adherent or non
adherent).ti,ab.
22 exp Ointments/
23 (ointment$ or cream$1 or gel$1).ti,ab.
24 or/18-23
25 exp Pain/
26 pain$.ti,ab.
27 or/25-26
28 24 and 27
29 17 or 28
30 exp Leg Ulcer/
31 (varicose ulcer$ or venous ulcer$ or leg ulcer$ or foot ulcer$ or (feet adj ulcer$) or stasis ulcer$).ti,ab.
32 or/30-31
33 29 and 32
Appendix 3. Ovid EMBASE search strategy
1 exp ANALGESIA/
2 exp Analgesic Agent/
3 exp CAPSAICIN/
4 capsaicin.ti,ab.
5 exp Opiate/
6 opioid$.ti,ab.
7 exp Nonsteroid Antiinflammatory Agent/
8 (non steroidal anti-inflammator$ or NSAID$).ti,ab.
9 or/1-8
10 exp Topical Drug Administration/
11 (topical or local).ti,ab.
12 or/10-11
13 9 and 12
14 exp Local Anesthetic Agent/
15 ((topical or local) adj3 (anaesthe$ or anesthe$)).ti,ab.
16 ((topical or local) adj3 analges$).ti,ab.
17 or/13-16
18 exp Wound Dressing/
19 exp Hydrogel Dressing/
20 exp Hydrogel/
21 exp Alginic Acid/
22 (dressing$ or hydrocolloid$ or alginate$ or hydrogel$ or foam or bead or film or films or tulle or gauze or non-adherent or non
adherent).ti,ab.
23 exp Ointment/
24 (ointment$ or cream$1 or gel$1).ti,ab.
25 or/18-24
26 exp Pain/
27 pain$.ti,ab.
28 or/26-27
29 25 and 28
30 17 or 29
31 exp Leg Ulcer/
32 (varicose ulcer$ or venous ulcer$ or leg ulcer$ or foot ulcer$ or (feet adj ulcer$) or stasis ulcer$).ti,ab.
33 or/31-32
34 30 and 33
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Appendix 4. EBSCO CINAHL search strategy
S31 S27 and S30
S30 S28 or S29
S29 TI (varicose ulcer* or venous ulcer* or leg ulcer* or foot ulcer* or feet N3 ulcer* or stasis ulcer ) or AB ( varicose ulcer* or venous
ulcer* or leg ulcer* or foot ulcer* or feet N3 ulcer* or stasis ulcer)
S28 Leg Ulcer
S27 S16 or S26
S26 S22 and S25
S25 S23 or S24
S24 TI pain* or AB pain*
S23 (MH “Pain+”)
S22 S17 or S18 or S19 or S20 or S21
S21 TI (ointment* or cream* or gel or gels) or AB (ointment* or cream* or gel or gels)
S20 (MH “Ointments”)
S19 TI (dressing* or hydrocolloid* or alginate* or hydrogel* or foam or bead or film or films or tulle or gauze or non-adherent or non
adherent) or AB (dressing* or hydrocolloid* or alginate* or hydrogel* or foam or bead or film or films or tulle or gauze or non-adherent
or nonadherent)
S18 (MH “Alginates”)
S17 (MH “Bandages and Dressings+”)
S16 S12 or S13 or S14 or S15
S15 TI (topical N3 analges* or local N3 analges*) or AB (topical N3 analges* or local N3 analges*)
S14 TI (topical N3 anaesthe* or topical N3 anesthe* or local N3 anaesthe* or local N3 anesthe*) or AB (topical N3 anaesthe* or topical
N3 anesthe* or local N3 anaesthe* or local N3 anesthe*) S13(MH “Anesthetics, Local+”)
S12 S8 and S11
S11 S9 or S10
S10 TI (topical or local) or AB (topical or local)
S9 (MH “Administration, Topical+”)
S8 S1 or S2 or S3 or S4 or S5 or S6 or S7
S7 TI (non steroidal anti-inflammator* or NSAID*) or AB (non steroidal anti-inflammator* or NSAID*)
S6 (MH “Antiinflammatory Agents, Non-Steroidal+”)
S5 TI opioid* or AB opioid*
S4 TI capsaicin or AB capsaicin
S3 (MH “Capsaicin”)
S2 (MH “Analgesics+”)
S1 (MH “Analgesia+”)
WH A T ’ S N E W
Last assessed as up-to-date: 9 May 2012.
Date Event Description
6 June 2012 New search has been performed Three new trials identified. One included for this update
(Arapoglou 2011) and two added as awaiting assessment
(Claeys 2011; Mosti 2010).
6 June 2012 New citation required but conclusions have not changed Third update, new search, no change to conclusions.
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H I S T O R Y
Protocol first published: Issue 4, 1998
Review first published: Issue 2, 1999
Date Event Description
11 March 2010 New citation required and conclusions have changed Two additional studies included (Gottrup 2008; Ro-
manelli 2009a).
11 March 2010 New search has been performed 2nd update, new searches.
11 October 2008 New search has been performed Converted to new review format.
7 November 2002 New citation required and conclusions have changed Substantive amendment, 5 additional trials included
C O N T R I B U T I O N S O F A U T H O R S
MB and EAN developed the protocol, identified papers and extracted data for the original review. Both MB and EAN drafted the
review, sifted the updated searches and contributed to the writing of the first and second review updates. For this, third, update, MB
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statistical and narrative synthesis for this update. MB is the guarantor of the review.
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